BLOOD CANCER UNITED INC: Form 990, tax year 2021

View the entire original 990 at ProPublica ↗

Organization: BLOOD CANCER UNITED INC (EIN 13-5644916)
Tax period: 2021-07-01 to 2022-06-30
Filed: 2023-02-03
IRS object ID: 202320349349301012
Schema version: 2021v4.0
Source: Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header
Form 990
Schedule A
Schedule B
Schedule C
Schedule D
Schedule F
Schedule G
Schedule I
Schedule J
Schedule M
Schedule O
Schedule R

Return header ReturnHeader

Field	Value	IRS element (for citing)
Return	2023-02-03T11:54:18-05:00	ReturnTs
Tax Period End	2022-06-30	TaxPeriodEndDt

Preparer Firm PreparerFirmGrp

Field	Value	IRS element (for citing)
Preparer Firm EIN	135565207	PreparerFirmEIN

Preparer Firm Name PreparerFirmName

Field	Value	IRS element (for citing)
Business Name Line1	KPMG LLP	BusinessNameLine1Txt

Preparer US Address PreparerUSAddress

Field	Value	IRS element (for citing)
Address Line1	345 PARK AVENUE	AddressLine1Txt
City	NEW YORK	CityNm
State Abbreviation	NY	StateAbbreviationCd
ZIP	101540102	ZIPCd

Field	Value	IRS element (for citing)
Return Type	990	ReturnTypeCd
Tax Period Begin	2021-07-01	TaxPeriodBeginDt

Filer Filer

Field	Value	IRS element (for citing)
EIN	135644916	EIN

Business Name BusinessName

Field	Value	IRS element (for citing)
Business Name Line1	THE LEUKEMIA & LYMPHOMA SOCIETYINC	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
Business Name Control	LEUK	BusinessNameControlTxt
Phone	9149495213	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	3 INTERNATIONAL DRIVE SUITE 200	AddressLine1Txt
City	RYE BROOK	CityNm
State Abbreviation	NY	StateAbbreviationCd
ZIP	10573	ZIPCd

Business Officer BusinessOfficerGrp

Field	Value	IRS element (for citing)
Person	GORDON MILLER JR	PersonNm
Person Title	EVP CHIEF FIN OFFICE	PersonTitleTxt
Phone	9148218908	PhoneNum
Signature	2023-02-01	SignatureDt
Discuss With Paid Preparer	Yes (true)	DiscussWithPaidPreparerInd

Signing Officer SigningOfficerGrp

Person Full Name PersonFullName

Field	Value	IRS element (for citing)
Person First	GORDON	PersonFirstNm
Person Last	MILLER	PersonLastNm

Field	Value	IRS element (for citing)
SSN	XXX-XX-XXXX	SSN

Preparer Person PreparerPersonGrp

Field	Value	IRS element (for citing)
Preparer Person	DEVIN L DUNCAN	PreparerPersonNm
PTIN	P01249521	PTIN
Phone	2127589700	PhoneNum
Preparation	2023-02-03	PreparationDt

Field	Value	IRS element (for citing)
Tax	2021	TaxYr
Build TS	2023-03-07 01:45:13Z	BuildTS

Form 990 IRS990

Field	Value	IRS element (for citing)
Principal Officer	LOUIS J DEGENNARO	PrincipalOfficerNm

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	3 INTERNATIONAL DRIVE SUITE 200	AddressLine1Txt
City	RYE BROOK	CityNm
State Abbreviation	NY	StateAbbreviationCd
ZIP	10573	ZIPCd

Field	Value	IRS element (for citing)
Gross Receipts	$675,392,108	GrossReceiptsAmt
Group Return For Affiliates	false	GroupReturnForAffiliatesInd
Organization501c3	Yes (X)	Organization501c3Ind
Website Address	WWW.LLS.ORG	WebsiteAddressTxt
Type Of Organization Corp	Yes (X)	TypeOfOrganizationCorpInd
Formation	1949	FormationYr
Legal Domicile State	NY	LegalDomicileStateCd
Activity Or Mission	OUR MISSION IS TO CURE LEUKEMIA, LYMPHOMA, HODGKIN'S DISEASE AND MYELOMA, AND IMPROVE THE QUALITY OF LIFE OF PATIENTS AND THEIR FAMILIES.	ActivityOrMissionDesc
Voting Members Governing Body	19	VotingMembersGoverningBodyCnt
Voting Members Independent	19	VotingMembersIndependentCnt
Total Employee	1177	TotalEmployeeCnt
Total Volunteers	3000000	TotalVolunteersCnt
Total Gross UBI	$0	TotalGrossUBIAmt
PY Contributions Grants	$441,317,494	PYContributionsGrantsAmt
CY Contributions Grants	$400,540,019	CYContributionsGrantsAmt
PY Program Service Revenue	$12,281,240	PYProgramServiceRevenueAmt
CY Program Service Revenue	$11,597,762	CYProgramServiceRevenueAmt
PY Investment Income	$12,298,324	PYInvestmentIncomeAmt
CY Investment Income	$6,919,696	CYInvestmentIncomeAmt
PY Other Revenue	$11,766,658	PYOtherRevenueAmt
CY Other Revenue	$7,939,727	CYOtherRevenueAmt
PY Total Revenue	$477,663,716	PYTotalRevenueAmt
CY Total Revenue	$426,997,204	CYTotalRevenueAmt
PY Grants And Similar Paid	$152,554,274	PYGrantsAndSimilarPaidAmt
CY Grants And Similar Paid	$299,213,836	CYGrantsAndSimilarPaidAmt
CY Benefits Paid To Members	$0	CYBenefitsPaidToMembersAmt
PY Salaries Comp Emp Bnft Paid	$113,748,897	PYSalariesCompEmpBnftPaidAmt
CY Salaries Comp Emp Bnft Paid	$112,055,516	CYSalariesCompEmpBnftPaidAmt
PY Total Prof Fndrsng Expns	$9,126,288	PYTotalProfFndrsngExpnsAmt
CY Total Prof Fndrsng Expns	$5,554,287	CYTotalProfFndrsngExpnsAmt
CY Total Fundraising Expense	$50,603,358	CYTotalFundraisingExpenseAmt
PY Other Expenses	$84,418,720	PYOtherExpensesAmt
CY Other Expenses	$101,798,755	CYOtherExpensesAmt
PY Total Expenses	$359,848,179	PYTotalExpensesAmt
CY Total Expenses	$518,622,394	CYTotalExpensesAmt
PY Revenues Less Expenses	$117,815,537	PYRevenuesLessExpensesAmt
CY Revenues Less Expenses	-$91,625,190	CYRevenuesLessExpensesAmt
Total Assets BOY	$743,613,782	TotalAssetsBOYAmt
Total Assets EOY	$693,676,206	TotalAssetsEOYAmt
Total Liabilities BOY	$229,841,284	TotalLiabilitiesBOYAmt
Total Liabilities EOY	$321,732,744	TotalLiabilitiesEOYAmt
Net Assets Or Fund Balances BOY	$513,772,498	NetAssetsOrFundBalancesBOYAmt
Net Assets Or Fund Balances EOY	$371,943,462	NetAssetsOrFundBalancesEOYAmt
Info In Schedule O Part III	Yes (X)	InfoInScheduleOPartIIIInd
Mission	OUR MISSION IS TO CURE LEUKEMIA, LYMPHOMA, HODGKIN'S DISEASE AND MYELOMA, AND IMPROVE THE QUALITY OF LIFE OF PATIENTS AND THEIR FAMILIES.	MissionDesc
Significant New Program Srvc	false	SignificantNewProgramSrvcInd
Significant Change	false	SignificantChangeInd
Expense	$83,342,500	ExpenseAmt
Grant	$48,847,932	GrantAmt
Revenue	$11,597,762	RevenueAmt
Desc	A) RESEARCH PROGRAMS: AT LLS, WE ARE PUSHING BOUNDARIES TOWARD POWERFUL NEW THERAPIES. WE PROPEL GROUNDBREAKING CANCER TREATMENTS THROUGH ALL PHASES OF THE DRUG APPROVAL PROCESS AND ARE PROUD THAT OUR SUPPORT HAS BEEN KEY TO ADVANCING 75% OF THE ALMOST 100 BLOOD CANCER TREATMENT APPROVALS OVER THE LAST FIVE YEARS. AS WE CONTINUED TO SUPPORT THE SEARCH FOR LIFESAVING AND LESS TOXIC TREATMENTS IN 2022, WE INVESTED IN EXCITING RESEARCH FRONTIERS, INCLUDING PRECISION MEDICINE, IMMUNOTHERAPY, AND LINKS BETWEEN MUTATIONS AND BLOOD CANCER-ADVANCEMENTS THAT ARE CHANGING THE PARADIGM OF CANCER TREATMENT. IN THE PROCESS, WE PROPELLED SEVERAL NOVEL SCIENCE INITIATIVES TO NEW HEIGHTS-MANY OF WHICH HARDLY SEEMED POSSIBLE JUST A SHORT TIME AGO. WITH ADVISORY INPUT FROM RECOGNIZED BIOMEDICAL RESEARCH EXPERTS, LLS FUNDS EXEMPLARY PROJECTS ACROSS THE ENTIRE RESEARCH CONTINUUM RELEVANT TO IMPROVE OUTCOMES FOR BLOOD CANCER PATIENTS, FROM BASIC LABORATORY SCIENCE THROUGH CLINICAL TRIALS, AND FROM INVESTIGATOR-INITIATED RESEARCH TO PRIVATE-SECTOR DRUG DEVELOPMENT ALLIANCES. LLS IS DELIBERATE AND PURPOSEFUL IN FINDING AND SUPPORTING RESEARCH THAT IS MOST LIKELY TO HELP PATIENTS AS SOON AS POSSIBLE. TO DATE, LLS HAS INVESTED OVER 1.6 BILLION IN RESEARCH AIMED AT HELPING ALL BLOOD CANCER PATIENTS LIVE BETTER, LONGER LIVES. OUR SUSTAINED RESEARCH INVESTMENT OVER MULTIPLE DECADES HAS PAID OFF HANDSOMELY. THIS IS BEST DEMONSTRATED BY OUR SEMINAL INVESTMENT IN CHIMERIC ANTIGEN RECEPTOR T CELL (CAR T) THERAPY STARTING IN 1990 THAT, SINCE 2017, HAS TRANSLATED INTO A 12 FDA-APPROVED CAR T THERAPIES FOR ACUTE B-CELL LEUKEMIA, NON-HODGKIN LYMPHOMA, AND MULTIPLE MYELOMA. CAR T THERAPY HAS IN SOME CASES PRODUCED CURES IN PATIENTS WHO HAVE FAILED ALL OTHER THERAPEUTIC OPTIONS. IN FISCAL YEAR 2022, LLS SUPPORTED RESEARCH IN THE U.S., CANADA AND 9 OTHER COUNTRIES WITH A TOTAL RESEARCH DISBURSEMENT OF APPROXIMATELY 54.6 MILLION. RESEARCH FUNDING WAS DISTRIBUTED ACROSS ALL BLOOD CANCERS. IMPACT RESEARCH GRANTS TO ADDRESS UNEQUAL REPRESENTATION OF UNDERSERVED POPULATIONS IN CLINICAL TRIALS, IN MAY WE INTRODUCED IMPACT (INFLUENTIAL MEDICINE PROVIDING ACCESS TO CLINICAL TRIALS) RESEARCH GRANTS. AN INITIAL FIVE-YEAR INVESTMENT OF 3.75 MILLION WAS ALLOCATED TO MAYO CLINIC, VANDERBILT UNIVERSITY MEDICAL CENTER, AND WEILL CORNELL MEDICINE IN NEW YORK CITY. WE NOW HAVE SIX IMPACT RESEARCH GRANTS IN PLACE SINCE OCTOBER 2022. THE IMPACT GRANTS WILL HELP THESE MAJOR CANCER CENTERS EXPAND CLINICAL TRIAL ACCESS TO LOCAL COMMUNITY-BASED HOSPITALS AND CLINICS WITH SUBSTANTIAL UNDERSERVED POPULATIONS. THE GOAL IS TO INCREASE TRIAL ENROLLMENT AMONG TRADITIONALLY UNDERSERVED POPULATIONS, INCLUDING RACIAL AND ETHNIC MINORITIES, RURAL RESIDENTS, AND INDIVIDUALS WITH LOW INCOME, TO AT LEAST 20%, THEREBY EXPANDING ACCESS TO STATE-OF-THE-ART THERAPIES TO A BROADER SWATH OF NEWLY DIAGNOSED BLOOD CANCER PATIENTS. THERAPY ACCELERATION PROGRAM (TAP) SINCE 2007, OUR INNOVATIVE VENTURE PHILANTHROPY INITIATIVE, THE LLS THERAPY ACCELERATION PROGRAM (TAP), HAS PARTNERED WITH OVER 70 BIOTECHNOLOGY COMPANIES AND ACADEMIC RESEARCHERS TO EXTEND THE THERAPEUTIC LANDSCAPE IN LEUKEMIA, LYMPHOMA, AND MULTIPLE MYELOMA BY INVESTING OVER 130 MILLION DOLLARS, AND SO FAR, LEADING TO 3 FDA APPROVALS. CURRENTLY, THERE ARE OVER 20 ACTIVE CLINICAL STUDIES WITH TAP-SUPPORTED THERAPIES, INCLUDING 4 LATE- STAGE CLINICAL STUDIES WITH CLINICAL DATA EXPECTED IN THE NEXT YEAR OR TWO THAT COULD LEAD TO NEW FDA APPROVALS FOR BLOOD CANCER PATIENTS. IN 2022, WE MADE FOUR INVESTMENTS IN COMPANIES DEVELOPING NEXT-GENERATION IMMUNOTHERAPIES INCLUDING TWO FROM EUROPE. THESE INVESTMENTS GO BEYOND THE TRADITIONAL T CELL THERAPY SUCH AS CAR-T OR BI-SPECIFICS AND INCLUDE TWO CHECKPOINT INHIBITORS USING MACROPHAGES OR MYELOID CELLS TO ELICIT THE ANTI-CANCER EFFECTS. WE ALSO INVESTED IN COMPANIES DEVELOPING NOVEL ANTIBODIES, ONE A GAMMA-DELTA T CELL ACTIVATING ANTIBODY FOR A VARIETY OF BLOOD CANCERS AND ANOTHER ANTIBODY FOR A NOVEL TARGET IN PATIENTS WITH RARE BLOOD CANCERS INCLUDING LARGE GRANULAR LYMPHOCYTIC LEUKEMIA AND CYTOTOXIC LYMPHOMAS WHERE THERE IS NO STANDARD OF CARE AND CURRENT THERAPIES ARE TOO TOXIC FOR PATIENTS. ALL FOUR COMPANIES ARE IN ACTIVE CLINICAL DEVELOPMENT IN BLOOD CANCERS. NATIONAL PATIENT REGISTRY COVID INFORMATION THE ONGOING COVID-19 PANDEMIC ENGENDERED A HOST OF FEARS AND QUESTIONS FOR THE BLOOD CANCER COMMUNITY. WHEN PATIENT CONCERNS AROSE ABOUT WHETHER THE NEW VACCINES WOULD PROTECT THEM, LLS STEPPED IN TO FIND ANSWERS. IN FEBRUARY 2021, LLS ACTIVATED THE LLS NATIONAL PATIENT REGISTRY, A PROJECT SUPPORTED BY ETHEL AND BERNARD GARIL IN MEMORY OF THEIR SON, MICHAEL, WHO SUCCUMBED TO ACUTE LYMPHOBLASTIC LEUKEMIA. MORE THAN 10,000 BLOOD CANCER PATIENTS ANSWERED THE CALL TO JOIN THE REGISTRY AS "CITIZEN SCIENTISTS." THIS ALLOWED US TO GENERATE THE LARGEST DATA SET REPORTED TO DATE ON VACCINE SAFETY AND EFFICACY(INCLUDING BOOSTERS) ACROSS ALL MAJOR BLOOD CANCER AND TREATMENT TYPES. THIS INFORMATION HAS HELPED PATIENTS, HEALTHCARE PROVIDERS, AND PUBLIC HEALTH OFFICIALS MAKE MORE INFORMED CHOICES ABOUT COVID-19 PREVENTION. CLINICAL TRIALS BEAT AML MASTER TRIAL BEGINNING NOVEMBER 2016, LLS LAUNCHED THE BEAT AML MASTER TRIAL, A COLLABORATIVE CLINICAL TRIAL TESTING SEVERAL NOVEL TARGETED THERAPIES FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) DESIGNED TO FACILITATE FDA APPROVAL OF NEW DRUGS AND CHANGE THE TREATMENT PARADIGM FOR PATIENTS DIAGNOSED WITH AML BY DEVELOPING MORE INDIVIDUALIZED, EFFECTIVE TREATMENT APPROACHES. THE MASTER TRIAL INVOLVES COLLABORATIONS WITH MULTIPLE MEDICAL INSTITUTIONS, DRUG COMPANIES, A GENOMIC PROVIDER, A CLINICAL RESEARCH ORGANIZATION, AND THE FDA, ALL OF WHOM HAVE COMMITTED TO WORKING COLLABORATIVELY. PEDAL MASTER TRIAL IN 2022, LLS LAUNCHED LLS' PEDIATRIC ACUTE LEUKEMIA (PEDAL) MASTER CLINICAL TRIAL. THIS UNPRECEDENTED INTERNATIONAL COLLOBORATION BETWEEN LLS, THE NATIONAL CANCER INSTITUTE (NCI), THE CHILDREN'S ONCOLOGY GROUP (OCG) AND OTHER PARTNERS BREAKS NEW GROUND, BRINGING PRECISION MEDICINE TO THE TREATMENT OF PEDIATRIC RELAPSED ACUTE LEUKEMIA. RATHER THAN A "ONE SIZE FITS ALL" APPROACH, PEDAL USES GENOMICS AND OTHER BIOMARKERS TO CUSTOMIZE TREATMENT, ALLOWING INNOVATIVE THERAPIES TO BE MATCHED TO PATIENTS BASED ON THEIR UNIQUE TUMOR BIOLOGY. A WIDE RANGE OF TRIAL SCREENIN LOCATIONS - SPANNING EUROPE, AUSTRALIA, NEW ZEALAND, CANADA, AND OVER 200 US SITES - ENSURES WIDESPREAD PARTICIPATION. ARKANSAS CHILDRESN'S HOSPITAL BECAME THE FIRST US THERAPEUTIC TRIAL SITE IN 2022, WITH MORE TO COME.	Desc

Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp

Field	Value	IRS element (for citing)
Expense	$296,248,725	ExpenseAmt
Grant	$250,365,904	GrantAmt
Desc	B) PATIENT & COMMUNITY SERVICES: AN ESTIMATED 1.5 MILLION PEOPLE ACROSS THE UNITED STATES (US) ARE CURRENTLY LIVING WITH OR ARE IN REMISSION FROM LEUKEMIA, LYMPHOMA AND MYELOMA. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) OFFERS AN ARRAY OF FREE, COMPREHENSIVE RESOURCES TO BLOOD CANCER PATIENTS, CAREGIVERS, FAMILIES AND FRIENDS OF PATIENTS, ADVOCATES, HEALTHCARE PROFESSIONALS AND THE PUBLIC. LLS IS COMMITTED TO PROVIDING THE MOST ACCURATE AND UP-TO-DATE BLOOD CANCER INFORMATION. PROFESSIONAL VOLUNTEER CLINICAL ADVISORS WORK WITH LLS STAFF TO REVIEW ALL OF THE INFORMATION LLS PROVIDES THROUGH HEALTHCARE PROFESSIONAL AND PATIENT EDUCATION PROGRAMS, PUBLICATIONS AND THE LLS WEBSITE. SUPPORT SERVICES ARE PROVIDED BY PROFESSIONALS OR RIGOROUSLY TRAINED PEER VOLUNTEERS. ALL RESOURCES ARE PROVIDED THROUGH A VARIETY OF MEDIA - PRINT, ONLINE, BY PHONE, AND FACE-TO-FACE IN COMMUNITIES. A NUMBER OF RESOURCES ARE AVAILABLE IN SPANISH FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. FINANCIAL ASSISTANCE OUR FINANCIAL ASSISTANCE PROGRAMS AIM TO LESSEN THE ECONOMIC TOLL ON PATIENTS AND FAMILIES TO HELP PATIENTS AFFORD LIFE-SAVING TREATMENTS. TO COUNTER CONTINUALLY RISING DRUG PRICES AND ALLEVIATE THE BURDENS FELT BY PATIENTS COPING WITH BLOOD CANCER, WE PROVIDED MORE THAN 75,400 PATIENTS WITH OVER 384M IN ASSISTANCE AWARDED, A 59% INCREASE OVER LAST YEAR. THE LION'S SHARE-OVER 371 MILLION- AWARDED TO SUPPORTED PATIENTS' INSURANCE PREMIUMS AND TREATMENT-RELATED CO-PAY AND CO-INSURANCE OUT OF POCKET COSTS THROUGH OUR CO-PAY ASSISTANCE PROGRAM. IN KEEPING WITH OUR COMMITMENT TO DIVERSITY, EQUITY, AND INCLUSION, LLS RECOGNIZES THAT NEED EXISTS THROUGHOUT ALL GEOGRAPHIC REGIONS AND WITHIN ALL PATIENT POPULATIONS, INCLUDING THOSE TRADITIONALLY UNDERREPRESENTED. IN FY22, FINANCIAL ASSISTANCE WAS PROVIDED TO PATIENTS WHO RESIDED IN 82% OF ALL U.S. COUNTIES AND 74% OF THE COUNTIES ACROSS THE U.S. WITH THE HIGHEST POVERTY RATES. CO-PAY ASSISTANCE PROGRAM THE CO-PAY ASSISTANCE PROGRAM SUPPORTS QUALIFYING BLOOD CANCER PATIENTS MEET THEIR HEALTH INSURANCE OR MEDICARE PLAN PART B OR D PREMIUMS OR CO- PAYMENT OBLIGATIONS RELATED TO TREATING THEIR BLOOD CANCER DIAGNOSIS. PATIENTS WITH PRESCRIPTION DRUG COVERAGE, MEDICARE BENEFICIARIES UNDER MEDICARE PART B AND/OR MEDICARE PART D, MEDICARE SUPPLEMENTARY HEALTH INSURANCE OR MEDICARE ADVANTAGE SHOULD CHECK WITH LLS TO SEE IF THEY MEET ELIGIBILITY REQUIREMENTS TO RECEIVE FINANCIAL SUPPORT. CO-PAY ASSISTANCE IS SUBJECT TO FUNDING AVAILABILITY BY SPECIFIC BLOOD CANCER DIAGNOSIS. IN 2022, CO-PAY ASSISTANCE WAS PROVIDED TO OVER 36,800 PATIENTS. SUSAN LANG PRE CAR T-CELL THERAPY TRAVEL ASSISTANCE PROGRAM LLS PROVIDED OVER 420 GRANTS, EACH 2,500, FOR TREATMENT-RELATED TRANSPORTATION AND LODGING COSTS FOR PATIENTS WHO ARE BEING EVALUATED TO RECEIVE CAR T-CELL THERAPY AS EITHER STANDARD TREATMENT OR A CLINICAL TRIAL. SUSAN LANG PAY-IT-FORWARD PATIENT TRAVEL ASSISTANCE PROGRAM LLS AWARDED A 500 GRANT TO OVER 11,050 PATIENTS FOR TREATMENT-RELATED TRANSPORTATION AND LODGING COSTS. URGENT NEED PROGRAM IN PARTNERSHIP WITH MOPPIE'S LOVE AND CHARLIE'S FUND, LLS PROVIDED A 500 GRANT TO NEARLY 11,750 PATIENTS AND FAMILIES IN ACUTE FINANCIAL NEED FOR NON-MEDICAL LIVING EXPENSES-INCLUDING RENT, UTILITIES, AND FOOD. PATIENT AID PROGRAM LLS AWARDED ONE-TIME STIPENDS OF 100 TO OVER 15,400 PATIENTS TO HELP OFFSET NON-MEDICAL EXPENSES. SCHOLARSHIP FOR BLOOD CANCER SURVIVORS IN 2022, THE LLS SCHOLARSHIP FOR BLOOD CANCER SURVIVORS PROVIDED UP TO 7,500 IN TUITION SUPPORT TO 100 PATIENTS, FOR VIRTUAL OR IN-PERSON VOCATIONAL, TWO-YEAR, OR FOUR-YEAR UNDERGRADUATE EDUCATION.	Desc

Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp

Field	Value	IRS element (for citing)
Expense	$19,723,379	ExpenseAmt
Desc	C) PUBLIC HEALTH EDUCATION: LLS BELIEVES KNOWLEDGE IS POWER. AS ALWAYS, LLS HAS OFFERED THEIR INFORMATIONAL PROGRAMS IN VIRTUAL FORMATS, CONTINUING TO PROVIDE VITALLY NEEDED EDUCATION AND EMOTIONAL SUPPORT FOR THOSE IMPACTED BY BLOOD CANCER. ONGOING PANDEMIC CONCERNS TRAINED ONCOLOGY INFORMATION SPECIALISTS IN OUR INFORMATION RESOURCE CENTER (IRC) WERE AVAILABLE TO ANSWER PANDEMIC-RELATED AND OTHER QUESTIONS. NEARLY 26,000 INTERACTIONS BETWEEN THE IRC AND PATIENTS AND CAREGIVERS TOOK PLACE, WITH AVERAGE CALL LENGTHS UP 14% OVER 2021. FACILITATING CLINICAL TRIAL ACCESS THE LLS CLINICAL TRIAL SUPPORT CENTER (CTSC) GREW THROUGHOUT THE YEAR AS WE INCREASED OUR BI-LINGUAL AND PEDIATRIC EXPERTISE AMONG THE CTSC NURSE NAVIGATORS, AND CONTINUED TO EXPAND THE POSSIBILITY OF POSITIVE OUTCOMES FOR PATIENTS BY MATCHING THEM TO SUITABLE CLINICAL TRIALS. OUR NURSE NAVIGATORS ASSISTED 1,005 PATIENTS (ABOUT THE SAME AS IN 2021). OF THE 751 NEW PATIENTS ASSISTED, 19% ENTERED A TRIAL. OUTREACH TO UNDERSERVED GROUPS WE AUGMENTED EFFORTS TO EXPAND ACCESS TO LLS SERVICES AND RESOURCES BY BOLSTERING RELATIONS WITH COMMUNITY GROUPS AND LEADERS, NOTABLY IN THE BLACK AND LATINO COMMUNITIES, AND INCREASED OUR NUMBER OF BILINGUAL VOLUNTEERS. WE ALSO INCREASED ACCESSIBILITY OF OUR EDUCATION PROGRAMS TO RURAL PATIENTS AND FAMILIES VIA OUR VIRTUAL OFFERINGS. MOREOVER, WE EXPANDED PARTNERSHIPS WITH AFFINITY GROUPS INCLUDING: THE NATIONAL COALITION OF 100 BLACK WOMEN, THE BLACK CAUCUS OF THE AMERICAN LIBRARY, VISIONS Y COMPROMISO AND THE MEXICAN CONSULATE'S VENTANILLA DE SALUD PROGRAM. THE LLS MYELOMA LINK PROGRAM, LAUNCHED IN 2017, CONTINUED TO GAIN TRACTION. WE IMPROVED UNDERSTANDING OF TREATMENT OPTIONS BY PROVIDING IMPORTANT INFORMATION TO AFRICAN AMERICANS, WHO ARE TWICE AS LIKELY TO BE DIAGNOSED WITH MULTIPLE MYELOMA AS CAUCASIAN AMERICANS. IN 2022, LLS REACHED NEARLY 22,000 PEOPLE THROUGH MORE THAN 60 MYELOMA LINK EDUCATION AND OUTREACH ACTIVITIES IN 13 CITIES. EDUCATION AND PATIENT CONNECTIONS OUR VIRTUAL EDUCATION PROGRAMS PROVIDED BOTH PATIENTS AND FAMILIES, AS WELL AS HEALTH CARE PROFESSIONALS, ACCESS TO CONTENT INCLUDING BLOOD CANCER CONFERENCES, LOCAL EDUCATION PROGRAMS, NATIONAL WEBINARS, VIDEOS, LECTURES, AND PODCASTS. LLS'S HIGHLY VIEWED WEBSITE CONTINUES TO PROVIDE THE MOST UP TO DATE BLOOD CANCER INFORMATION INCLUDING ACCESS TO BLOGS, BOOKLETS, WORKBOOKS, FACT SHEETS AND MORE. IN ADDITION, 1,060 CANCER PATIENTS WERE PROVIDED WITH PERSONALIZED NUTRITION CONSULTATIONS BY LLS'S REGISTERED DIETITIAN. OUR PATIENT & COMMUNITY OUTREACH TEAM CONTINUED TO BRING PATIENTS TOGETHER VIA ONLINE LOCAL SUPPORT GROUPS AND CHATS. THE PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM MATCHED NEARLY 2,100 PATIENTS (UP 17% FROM 2021) WITH TRAINED VOLUNTEERS FACING THE SAME DISEASE, HELPING TO AVERT PANDEMIC-RELATED ISOLATION. IN ADDITION, MEMBERSHIP IN LLS COMMUNITY-OUR ONLINE SOCIAL NETWORK- WAS 19,181, AN INCREASED 8% OVER 2021.	Desc

Prog Srvc Accom Acty Other ProgSrvcAccomActyOtherGrp

Field	Value	IRS element (for citing)
Expense	$11,983,999	ExpenseAmt
Desc	D) PROFESSIONAL EDUCATION: LLS SERVES THE EDUCATIONAL NEEDS OF THE MEDICAL AND RESEARCH COMMUNITY THROUGH A NUMBER OF PROFESSIONAL EDUCATION SYMPOSIA OFFERED THROUGHOUT THE YEAR. THE EDUCATIONAL PROGRAM OFFERS VARYING FORMATS TO FACILITATE THE EXCHANGE OF INFORMATION AND IDEAS ON THE NEWEST DEVELOPMENTS IN CANCER RESEARCH AND TREATMENT. UPCOMING AND ARCHIVED CE/CME PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/CE. IN FY 2022: -LLS PROVIDED 14 CME/CE-GRANTING VIRTUAL EDUCATIONAL PROGRAMS, WITH 873 HEALTHCARE PROFESSIONALS IN ATTENDANCE. - OVER 28,000 PATIENTS AND PROFESSIONALS PARTICIPATED IN LIVE EDUCATION PROGRAMS DELIVERED VIRTUALLY AS WELL AS DELIVERED IN PERSON, LOCALLY AND REGIONALLY. --THERE WERE 104,173 PAGE VIEWS FOR ARCHIVED WEB PROGRAMS, 35,663 VIRTUAL LECTURE VIEWS AND 97,685 PODCAST DOWNLOADS.	Desc

Field	Value	IRS element (for citing)
Total Other Prog Srvc Expense	$11,983,999	TotalOtherProgSrvcExpenseAmt
Total Program Service Expenses	$411,298,603	TotalProgramServiceExpensesAmt
Described In Section501c3	Yes (true)	DescribedInSection501c3Ind
Schedule B Required	Yes (true)	ScheduleBRequiredInd
Political Campaign Acty	false	PoliticalCampaignActyInd
Lobbying Activities	Yes (true)	LobbyingActivitiesInd
Subject To Proxy Tax	false	SubjectToProxyTaxInd
Donor Advised Fund	false	DonorAdvisedFundInd
Conservation Easements	false	ConservationEasementsInd
Collections Of Art	Yes (true)	CollectionsOfArtInd
Credit Counseling	false	CreditCounselingInd
Donor Rstr Or Quasi Endowments	Yes (true)	DonorRstrOrQuasiEndowmentsInd
Report Land Building Equipment	Yes (true)	ReportLandBuildingEquipmentInd
Report Investments Other Sec	false	ReportInvestmentsOtherSecInd
Report Program Related Invst	false	ReportProgramRelatedInvstInd
Report Other Assets	false	ReportOtherAssetsInd
Report Other Liabilities	false	ReportOtherLiabilitiesInd
Include FIN48 Footnote	Yes (true)	IncludeFIN48FootnoteInd
Independent Audit Fincl Stmt	false	IndependentAuditFinclStmtInd
Consolidated Audit Fincl Stmt	Yes (true)	ConsolidatedAuditFinclStmtInd
School Operating	false	SchoolOperatingInd
Foreign Office	Yes (true)	ForeignOfficeInd
Foreign Activities	Yes (true)	ForeignActivitiesInd
More Than5000 K To Org	Yes (true)	MoreThan5000KToOrgInd
More Than5000 K To Individuals	false	MoreThan5000KToIndividualsInd
Professional Fundraising	Yes (true)	ProfessionalFundraisingInd
Fundraising Activities	Yes (true)	FundraisingActivitiesInd
Gaming Activities	false	GamingActivitiesInd
Operate Hospital	false	OperateHospitalInd
Grants To Organizations	Yes (true)	GrantsToOrganizationsInd
Grants To Individuals	Yes (true)	GrantsToIndividualsInd
Schedule J Required	Yes (true)	ScheduleJRequiredInd
Tax Exempt Bonds	false	TaxExemptBondsInd
Engaged In Excess Benefit Trans	false	EngagedInExcessBenefitTransInd
PY Excess Benefit Trans	false	PYExcessBenefitTransInd
Loan Outstanding	false	LoanOutstandingInd
Grant To Related Person	false	GrantToRelatedPersonInd
Business Rln With Org Mem	false	BusinessRlnWithOrgMemInd
Business Rln With Fam Mem	false	BusinessRlnWithFamMemInd
Business Rln With35 Ctrl Ent	false	BusinessRlnWith35CtrlEntInd
Deductible Non Cash Contri	Yes (true)	DeductibleNonCashContriInd
Deductible Art Contribution	false	DeductibleArtContributionInd
Terminate Operations	false	TerminateOperationsInd
Partial Liquidation	false	PartialLiquidationInd
Disregarded Entity	Yes (true)	DisregardedEntityInd
Related Entity	Yes (true)	RelatedEntityInd
Related Organization Ctrl Ent	Yes (true)	RelatedOrganizationCtrlEntInd
Transaction With Control Ent	false	TransactionWithControlEntInd
Trnsfr Exmpt Non Chrtbl Rltd Org	false	TrnsfrExmptNonChrtblRltdOrgInd
Activities Conducted Prtshp	false	ActivitiesConductedPrtshpInd
Schedule O Required	Yes (true)	ScheduleORequiredInd
IRP Document	253	IRPDocumentCnt
IRP Document W2 G	0	IRPDocumentW2GCnt
Backup Wthld Compliance	Yes (true)	BackupWthldComplianceInd
Employee	1177	EmployeeCnt
Employment Tax Returns Filed	Yes (true)	EmploymentTaxReturnsFiledInd
Unrelated Bus Incm Over Limit	false	UnrelatedBusIncmOverLimitInd
Foreign Financial Account	Yes (true)	ForeignFinancialAccountInd
Foreign Country	CA	ForeignCountryCd
Prohibited Tax Shelter Trans	false	ProhibitedTaxShelterTransInd
Taxable Party Notification	false	TaxablePartyNotificationInd
Nondeductible Contributions	false	NondeductibleContributionsInd
Quid Pro Quo Contributions	Yes (true)	QuidProQuoContributionsInd
Quid Pro Quo Contri Discl	Yes (true)	QuidProQuoContriDisclInd
Form8282 Property Disposed Of	false	Form8282PropertyDisposedOfInd
Rcv Fnds To Pay Prsnl Bnft Cntrct	false	RcvFndsToPayPrsnlBnftCntrctInd
Pay Premiums Prsnl Bnft Cntrct	false	PayPremiumsPrsnlBnftCntrctInd
Indoor Tanning Services	false	IndoorTanningServicesInd
Subj To Tax Rmnrtn Ex Prcht Pymt	false	SubjToTaxRmnrtnExPrchtPymtInd
Subject To Excs Tax Net Invst Inc	false	SubjectToExcsTaxNetInvstIncInd
Info In Schedule O Part VI	Yes (X)	InfoInScheduleOPartVIInd
Governing Body Voting Members	19	GoverningBodyVotingMembersCnt
Independent Voting Member	19	IndependentVotingMemberCnt
Family Or Business Rln	false	FamilyOrBusinessRlnInd
Delegation Of Mgmt Duties	false	DelegationOfMgmtDutiesInd
Change To Org Documents	Yes (true)	ChangeToOrgDocumentsInd
Material Diversion Or Misuse	false	MaterialDiversionOrMisuseInd
Members Or Stockholders	false	MembersOrStockholdersInd
Election Of Board Members	false	ElectionOfBoardMembersInd
Decisions Subject To Approva	false	DecisionsSubjectToApprovaInd
Minutes Of Governing Body	Yes (true)	MinutesOfGoverningBodyInd
Minutes Of Committees	Yes (true)	MinutesOfCommitteesInd
Officer Mailing Address	false	OfficerMailingAddressInd
Local Chapters	Yes (true)	LocalChaptersInd
Policies Reference Chapters	Yes (true)	PoliciesReferenceChaptersInd
Form990 Provided To Gvrn Body	Yes (true)	Form990ProvidedToGvrnBodyInd
Conflict Of Interest Policy	Yes (true)	ConflictOfInterestPolicyInd
Annual Disclosure Covered Prsn	Yes (true)	AnnualDisclosureCoveredPrsnInd
Regular Monitoring Enfrc	Yes (true)	RegularMonitoringEnfrcInd
Whistleblower Policy	Yes (true)	WhistleblowerPolicyInd
Document Retention Policy	Yes (true)	DocumentRetentionPolicyInd
Compensation Process CEO	Yes (true)	CompensationProcessCEOInd
Compensation Process Other	Yes (true)	CompensationProcessOtherInd
Investment In Joint Venture	false	InvestmentInJointVentureInd
States Where Copy Of Return Is Fld	AK	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	AL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	AR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	AZ	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	CA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	CO	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	CT	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	DE	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	DC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	FL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	GA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	HI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	ID	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	IL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	IN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	KS	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	KY	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	LA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MD	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	ME	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MO	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MS	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NH	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NJ	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NM	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NE	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NY	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OH	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OK	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	PA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	PR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	RI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	SC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	TN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	UT	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	VA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WV	StatesWhereCopyOfReturnIsFldCd
Own Website	Yes (X)	OwnWebsiteInd
Upon Request	Yes (X)	UponRequestInd

Books In Care Of Detail BooksInCareOfDetail

Field	Value	IRS element (for citing)
Person	GORDON MILLER JR	PersonNm
Phone	9148218935	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	3 INTERNATIONAL DRIVE	AddressLine1Txt
City	RYE BROOK	CityNm
State Abbreviation	NY	StateAbbreviationCd
ZIP	10573	ZIPCd

Form990 Part VII Section A Form990PartVIISectionAGrp (28 entries)

TitleTitleTxt	Average Hours Per WeekAverageHoursPerWeekRt	Average Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRt	OfficerOfficerInd	Reportable Comp From OrgReportableCompFromOrgAmt	Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt	Other CompensationOtherCompensationAmt	Highest Compensated EmployeeHighestCompensatedEmployeeInd	Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd
LOUIS J DEGENNARO
PRESIDENT &	40.00	1.00	Yes (X)	$1,011,186	$0	$51,204
GWEN NICHOLS MD
EVP CHIEF ME	40.00		Yes (X)	$609,795	$0	$43,790
TROY DUNMIRE
EVP CHIEF OP	40.00		Yes (X)	$593,456	$0	$24,936
GORDON MILLER JR
EVP CHIEF FI	40.00	1.00	Yes (X)	$482,778	$0	$55,947
DALE NISSENBAUM
EVP GEN COUN	40.00			$493,477	$0	$19,326	Yes (X)
COKER POWELL
SVP CHIEF DE	40.00			$439,953	$0	$65,803	Yes (X)
TOM OSGOOD
EVP CHIEF HR	40.00			$437,669	$0	$31,401	Yes (X)
VANESSA WHITE
SVP CHIEF AD	40.00			$424,061	$0	$39,696	Yes (X)
LEE M GREENBERGER
SVP CHIEF SC	40.00			$384,232	$0	$66,083	Yes (X)
RICHARD BAGGER
BOD MEMBER	4.00			$0	$0	$0		Yes (X)
MICHELE CAMERON
BOD MEMBER	4.00			$0	$0	$0		Yes (X)
RUBEN MESA MD FACP
AT LARGE	4.00		Yes (X)	$0	$0	$0		Yes (X)
CHRISTOPHER FLOWERS
BOD MEMBER	4.00			$0	$0	$0		Yes (X)
JOHN GREENE
BOD MEMBER	4.00			$0	$0	$0		Yes (X)
FRANCIE HELLER
BOD MEMBER	4.00			$0	$0	$0		Yes (X)
RALPH E LAWSON
BOD MEMBER	4.00			$0	$0	$0		Yes (X)
CASEY CUNNINGHAM MD
BOD MEMBER	4.00			$0	$0	$0		Yes (X)
JANICE GABRILOVE MD
BOD MEMBER	4.00			$0	$0	$0		Yes (X)
RENZO CANETTA MD
BOD MEMBER	4.00			$0	$0	$0		Yes (X)
KATHLEEN MERIWETHER
VICE CHAIR	4.00		Yes (X)	$0	$0	$0		Yes (X)
LYNNE O'BRIEN
BOD MEMBER	4.00			$0	$0	$0		Yes (X)
MARLA PERSKY
BOD MEMBER	4.00			$0	$0	$0		Yes (X)
RICHARD RENDINA
BOD MEMBER	4.00			$0	$0	$0		Yes (X)
ROBERT ROSEN
BOD MEMBER	4.00			$0	$0	$0		Yes (X)
JEFF SACHS
CHAIR	4.00		Yes (X)	$0	$0	$0		Yes (X)
BART SICHEL
BOD MEMBER	4.00			$0	$0	$0		Yes (X)
ALESSANDRA TOCCO
BOD MEMBER	4.00			$0	$0	$0		Yes (X)
FREDA WANG
SECRETARY/TR	4.00		Yes (X)	$0	$0	$0		Yes (X)

Field	Value	IRS element (for citing)
Total Reportable Comp From Org	$4,876,607	TotalReportableCompFromOrgAmt
Total Other Compensation	$398,186	TotalOtherCompensationAmt
Indiv Rcvd Greater Than100 K	249	IndivRcvdGreaterThan100KCnt
Former Ofcr Employees Listed	false	FormerOfcrEmployeesListedInd
Total Comp Greater Than150 K	Yes (true)	TotalCompGreaterThan150KInd
Compensation From Other Srcs	false	CompensationFromOtherSrcsInd

Contractor Compensation ContractorCompensationGrp (5 entries)

Address Line1ContractorAddress/USAddress/AddressLine1Txt	CityContractorAddress/USAddress/CityNm	State AbbreviationContractorAddress/USAddress/StateAbbreviationCd	ZIPContractorAddress/USAddress/ZIPCd	ServicesServicesDesc	CompensationCompensationAmt
SYNEOS HEALTH LLC
75 REMITTANCE DRIVE SUITE 3160	CHICAGO	IL	606753160	CLINICAL TRIAL	$12,330,415
PATIENT ADVOCATE FOUNDATION
421 BUTLER FARM RD	HAMPTON	VA	23666	PAT ASSIST PROC	$10,257,027
RESOURCE ONE
2900 EAST APACHE STREET	TULSA	OK	74110	DIRECT MARKETIN	$4,883,318
META PLATFORMS
1 HACKER WAY	MENLO PARK	CA	94025	ADVERTISING	$3,223,672
SALESFORCE
140 E 45TH ST	NEW YORK	NY	10017	SOFTWARE	$3,164,175

Field	Value	IRS element (for citing)
Cntrct Rcvd Greater Than100 K	159	CntrctRcvdGreaterThan100KCnt
Federated Campaigns	$335,805	FederatedCampaignsAmt
Fundraising	$158,942,124	FundraisingAmt
All Other Contributions	$241,262,090	AllOtherContributionsAmt
Noncash Contributions	$1,872,690	NoncashContributionsAmt
Total Contributions	$400,540,019	TotalContributionsAmt

Program Service Revenue ProgramServiceRevenueGrp

Field	Value	IRS element (for citing)
Desc	SERVICE REVENUE	Desc
Business	810000	BusinessCd
Total Revenue Column	$11,597,762	TotalRevenueColumnAmt
Related Or Exempt Func Income	$11,597,762	RelatedOrExemptFuncIncomeAmt

Field	Value	IRS element (for citing)
Total Program Service Revenue	$11,597,762	TotalProgramServiceRevenueAmt

Investment Income InvestmentIncomeGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$8,431,107	TotalRevenueColumnAmt
Exclusion	$8,431,107	ExclusionAmt

Royalties Revenue RoyaltiesRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$9,656,656	TotalRevenueColumnAmt
Exclusion	$9,656,656	ExclusionAmt

Gross Amount Sales Assets GrossAmountSalesAssetsGrp

Field	Value	IRS element (for citing)
Securities	$231,878,526	SecuritiesAmt

Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp

Field	Value	IRS element (for citing)
Securities	$233,389,937	SecuritiesAmt

Gain Or Loss GainOrLossGrp

Field	Value	IRS element (for citing)
Securities	-$1,511,411	SecuritiesAmt

Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp

Field	Value	IRS element (for citing)
Total Revenue Column	-$1,511,411	TotalRevenueColumnAmt
Exclusion	-$1,511,411	ExclusionAmt

Field	Value	IRS element (for citing)
Fundraising Gross Income	$13,288,038	FundraisingGrossIncomeAmt
Contri Rpt Fundraising Event	$158,942,124	ContriRptFundraisingEventAmt
Fundraising Direct Expenses	$15,004,967	FundraisingDirectExpensesAmt

Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp

Field	Value	IRS element (for citing)
Total Revenue Column	-$1,716,929	TotalRevenueColumnAmt
Exclusion	-$1,716,929	ExclusionAmt

Total Revenue TotalRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$426,997,204	TotalRevenueColumnAmt
Related Or Exempt Func Income	$11,597,762	RelatedOrExemptFuncIncomeAmt
Exclusion	$14,859,423	ExclusionAmt

Grants To Domestic Orgs GrantsToDomesticOrgsGrp

Field	Value	IRS element (for citing)
Total	$41,209,239	TotalAmt
Program Services	$41,209,239	ProgramServicesAmt

Grants To Domestic Individuals GrantsToDomesticIndividualsGrp

Field	Value	IRS element (for citing)
Total	$250,365,904	TotalAmt
Program Services	$250,365,904	ProgramServicesAmt

Foreign Grants ForeignGrantsGrp

Field	Value	IRS element (for citing)
Total	$7,638,693	TotalAmt
Program Services	$7,638,693	ProgramServicesAmt

Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp

Field	Value	IRS element (for citing)
Total	$2,091,645	TotalAmt
Program Services	$852,283	ProgramServicesAmt
Management And General	$964,653	ManagementAndGeneralAmt
Fundraising	$274,709	FundraisingAmt

Other Salaries And Wages OtherSalariesAndWagesGrp

Field	Value	IRS element (for citing)
Total	$88,505,319	TotalAmt
Program Services	$44,161,169	ProgramServicesAmt
Management And General	$24,395,966	ManagementAndGeneralAmt
Fundraising	$19,948,184	FundraisingAmt

Pension Plan Contributions PensionPlanContributionsGrp

Field	Value	IRS element (for citing)
Total	$2,518,213	TotalAmt
Program Services	$1,197,908	ProgramServicesAmt
Management And General	$744,063	ManagementAndGeneralAmt
Fundraising	$576,242	FundraisingAmt

Other Employee Benefits OtherEmployeeBenefitsGrp

Field	Value	IRS element (for citing)
Total	$12,346,404	TotalAmt
Program Services	$5,899,281	ProgramServicesAmt
Management And General	$3,610,032	ManagementAndGeneralAmt
Fundraising	$2,837,091	FundraisingAmt

Payroll Taxes PayrollTaxesGrp

Field	Value	IRS element (for citing)
Total	$6,593,935	TotalAmt
Program Services	$3,136,721	ProgramServicesAmt
Management And General	$1,948,327	ManagementAndGeneralAmt
Fundraising	$1,508,887	FundraisingAmt

Fees For Services Legal FeesForServicesLegalGrp

Field	Value	IRS element (for citing)
Total	$4,725,702	TotalAmt
Program Services	$2,835,421	ProgramServicesAmt
Management And General	$1,275,940	ManagementAndGeneralAmt
Fundraising	$614,341	FundraisingAmt

Fees For Services Accounting FeesForServicesAccountingGrp

Field	Value	IRS element (for citing)
Total	$525,457	TotalAmt
Management And General	$525,457	ManagementAndGeneralAmt

Fees For Services Lobbying FeesForServicesLobbyingGrp

Field	Value	IRS element (for citing)
Total	$2,481,864	TotalAmt
Program Services	$2,481,864	ProgramServicesAmt

Fees For Services Prof Fundraising FeesForServicesProfFundraising

Field	Value	IRS element (for citing)
Total	$5,554,287	TotalAmt
Fundraising	$5,554,287	FundraisingAmt

Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp

Field	Value	IRS element (for citing)
Total	$227,786	TotalAmt
Program Services	$185,052	ProgramServicesAmt
Management And General	$22,949	ManagementAndGeneralAmt
Fundraising	$19,785	FundraisingAmt

Fees For Services Other FeesForServicesOtherGrp

Field	Value	IRS element (for citing)
Total	$25,326,073	TotalAmt
Program Services	$14,532,268	ProgramServicesAmt
Management And General	$4,545,117	ManagementAndGeneralAmt
Fundraising	$6,248,688	FundraisingAmt

Advertising AdvertisingGrp

Field	Value	IRS element (for citing)
Total	$8,707,809	TotalAmt
Program Services	$5,462,742	ProgramServicesAmt
Management And General	$1,158,998	ManagementAndGeneralAmt
Fundraising	$2,086,069	FundraisingAmt

Office Expenses OfficeExpensesGrp

Field	Value	IRS element (for citing)
Total	$15,269,287	TotalAmt
Program Services	$9,381,269	ProgramServicesAmt
Management And General	$1,794,807	ManagementAndGeneralAmt
Fundraising	$4,093,211	FundraisingAmt

Information Technology InformationTechnologyGrp

Field	Value	IRS element (for citing)
Total	$13,589,410	TotalAmt
Program Services	$1,024,642	ProgramServicesAmt
Management And General	$10,094,213	ManagementAndGeneralAmt
Fundraising	$2,470,555	FundraisingAmt

Occupancy OccupancyGrp

Field	Value	IRS element (for citing)
Total	$7,379,563	TotalAmt
Program Services	$3,813,240	ProgramServicesAmt
Management And General	$1,630,868	ManagementAndGeneralAmt
Fundraising	$1,935,455	FundraisingAmt

Travel TravelGrp

Field	Value	IRS element (for citing)
Total	$1,716,709	TotalAmt
Program Services	$898,977	ProgramServicesAmt
Management And General	$398,793	ManagementAndGeneralAmt
Fundraising	$418,939	FundraisingAmt

Depreciation Depletion DepreciationDepletionGrp

Field	Value	IRS element (for citing)
Total	$3,963,430	TotalAmt
Program Services	$2,304,535	ProgramServicesAmt
Management And General	$1,000,913	ManagementAndGeneralAmt
Fundraising	$657,982	FundraisingAmt

Insurance InsuranceGrp

Field	Value	IRS element (for citing)
Total	$1,375,286	TotalAmt
Program Services	$812,084	ProgramServicesAmt
Management And General	$351,295	ManagementAndGeneralAmt
Fundraising	$211,907	FundraisingAmt

Other Expenses OtherExpensesGrp (2 entries)

DescDesc	TotalTotalAmt	Program ServicesProgramServicesAmt	Management And GeneralManagementAndGeneralAmt	FundraisingFundraisingAmt
RESEARCH AND DEVELOPMENT	$9,757,258	$9,753,950	$2,639	$669
MISCELLANEOUS	$6,753,121	$3,351,361	$2,255,403	$1,146,357

Total Functional Expenses TotalFunctionalExpensesGrp

Field	Value	IRS element (for citing)
Total	$518,622,394	TotalAmt
Program Services	$411,298,603	ProgramServicesAmt
Management And General	$56,720,433	ManagementAndGeneralAmt
Fundraising	$50,603,358	FundraisingAmt

Field	Value	IRS element (for citing)
Joint Costs	Yes (X)	JointCostsInd

Total Joint Costs TotalJointCostsGrp

Field	Value	IRS element (for citing)
Total	$14,309,133	TotalAmt
Program Services	$9,558,392	ProgramServicesAmt
Fundraising	$4,750,741	FundraisingAmt

Cash Non Interest Bearing CashNonInterestBearingGrp

Field	Value	IRS element (for citing)
BOY	$17,101,591	BOYAmt
EOY	$10,533,722	EOYAmt

Savings And Temp Cash Invst SavingsAndTempCashInvstGrp

Field	Value	IRS element (for citing)
BOY	$118,564,418	BOYAmt
EOY	$59,563,249	EOYAmt

Pledges And Grants Receivable PledgesAndGrantsReceivableGrp

Field	Value	IRS element (for citing)
BOY	$13,531,687	BOYAmt
EOY	$24,346,058	EOYAmt

Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp

Field	Value	IRS element (for citing)
BOY	$3,702,570	BOYAmt
EOY	$5,700,688	EOYAmt

Field	Value	IRS element (for citing)
Land Bldg Equip Cost Or Other Bss	$22,230,984	LandBldgEquipCostOrOtherBssAmt
Land Bldg Equip Accum Deprec	$11,696,883	LandBldgEquipAccumDeprecAmt

Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp

Field	Value	IRS element (for citing)
BOY	$10,748,048	BOYAmt
EOY	$10,534,101	EOYAmt

Investments Pub Traded Sec InvestmentsPubTradedSecGrp

Field	Value	IRS element (for citing)
BOY	$552,134,623	BOYAmt
EOY	$560,279,919	EOYAmt

Investments Other Securities InvestmentsOtherSecuritiesGrp

Field	Value	IRS element (for citing)
BOY	$20,423,995	BOYAmt
EOY	$20,361,812	EOYAmt

Investments Program Related InvestmentsProgramRelatedGrp

Field	Value	IRS element (for citing)
BOY	$7,406,850	BOYAmt
EOY	$2,356,657	EOYAmt

Total Assets TotalAssetsGrp

Field	Value	IRS element (for citing)
BOY	$743,613,782	BOYAmt
EOY	$693,676,206	EOYAmt

Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp

Field	Value	IRS element (for citing)
BOY	$28,917,585	BOYAmt
EOY	$29,802,071	EOYAmt

Grants Payable GrantsPayableGrp

Field	Value	IRS element (for citing)
BOY	$188,608,360	BOYAmt
EOY	$278,233,023	EOYAmt

Deferred Revenue DeferredRevenueGrp

Field	Value	IRS element (for citing)
BOY	$12,315,339	BOYAmt
EOY	$13,697,650	EOYAmt

Total Liabilities TotalLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$229,841,284	BOYAmt
EOY	$321,732,744	EOYAmt

Field	Value	IRS element (for citing)
Organization Follows FASB117	Yes (X)	OrganizationFollowsFASB117Ind

No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$328,718,773	BOYAmt
EOY	$301,387,942	EOYAmt

Donor Restriction Net Assets DonorRestrictionNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$185,053,725	BOYAmt
EOY	$70,555,520	EOYAmt

Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$513,772,498	BOYAmt
EOY	$371,943,462	EOYAmt

Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$743,613,782	BOYAmt
EOY	$693,676,206	EOYAmt

Field	Value	IRS element (for citing)
Reconcilation Revenue Expnss	-$91,625,190	ReconcilationRevenueExpnssAmt
Net Unrlzd Gains Losses Invst	-$50,203,846	NetUnrlzdGainsLossesInvstAmt
Method Of Accounting Accrual	Yes (X)	MethodOfAccountingAccrualInd
Accountant Compile Or Review	false	AccountantCompileOrReviewInd
FS Audited	Yes (true)	FSAuditedInd

FS Audited Basis FSAuditedBasisGrp

Field	Value	IRS element (for citing)
Consolidated Basis Fincl Stmt	Yes (X)	ConsolidatedBasisFinclStmtInd

Field	Value	IRS element (for citing)
Audit Committee	Yes (true)	AuditCommitteeInd
Federal Grant Audit Required	false	FederalGrantAuditRequiredInd

Schedule A IRS990ScheduleA

Field	Value	IRS element (for citing)
Public Organization170	Yes (X)	PublicOrganization170Ind

Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$419,570,497	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$372,750,094	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$427,419,530	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$441,317,494	CurrentTaxYearMinus1YearAmt
Current Tax Year	$400,540,019	CurrentTaxYearAmt
Total	$2,061,597,634	TotalAmt

Total Calendar Year170 TotalCalendarYear170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$419,570,497	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$372,750,094	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$427,419,530	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$441,317,494	CurrentTaxYearMinus1YearAmt
Current Tax Year	$400,540,019	CurrentTaxYearAmt
Total	$2,061,597,634	TotalAmt

Field	Value	IRS element (for citing)
Substantial Contributors Tot	$559,389,444	SubstantialContributorsTotAmt
Public Support Total170	$1,502,208,190	PublicSupportTotal170Amt

Gross Investment Income170 GrossInvestmentIncome170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$8,235,985	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$11,830,162	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$29,082,073	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$16,877,123	CurrentTaxYearMinus1YearAmt
Current Tax Year	$18,087,763	CurrentTaxYearAmt
Total	$84,113,106	TotalAmt

Other Income170 OtherIncome170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$70,000	CurrentTaxYearMinus4YearsAmt
Total	$70,000	TotalAmt

Field	Value	IRS element (for citing)
Total Support	$2,145,780,740	TotalSupportAmt
Gross Receipts Rltd Activities	$83,180,015	GrossReceiptsRltdActivitiesAmt
Public Support CY170	0.70010	PublicSupportCY170Pct
Public Support PY170	0.70390	PublicSupportPY170Pct
Thirty Thr Pct Suprt Tests CY170	Yes (X)	ThirtyThrPctSuprtTestsCY170Ind

Form990 Schedule A Part VI Form990ScheduleAPartVIGrp

Field	Value	IRS element (for citing)
Form And Line Reference	PART II, LINE 10	FormAndLineReferenceDesc
Explanation	OTHER MISC. REVENUE (YR 2017) 70,000	ExplanationTxt

Schedule B IRS990ScheduleB

Contributor Information ContributorInformationGrp

Field	Value	IRS element (for citing)
Contributor	RESTRICTED	ContributorNum

Contributor Business Name ContributorBusinessName

Field	Value	IRS element (for citing)
Business Name Line1	RESTRICTED	BusinessNameLine1

Contributor US Address ContributorUSAddress

Field	Value	IRS element (for citing)
Address Line1	RESTRICTED	AddressLine1
Address Line2	RESTRICTED	AddressLine2
City	RESTRICTED	City
State	RESTRICTED	State
ZIP Code	RESTRICTED	ZIPCode

Field	Value	IRS element (for citing)
Total Contributions	RESTRICTED	TotalContributionsAmt

Schedule C IRS990ScheduleC

Field	Value	IRS element (for citing)
Volunteers	Yes (true)	VolunteersInd
Paid Staff Or Management	Yes (true)	PaidStaffOrManagementInd
Media Advertisements	Yes (true)	MediaAdvertisementsInd
Media Advertisements	$219,672	MediaAdvertisementsAmt
Mailings Members	false	MailingsMembersInd
Publications Or Broadcast	Yes (true)	PublicationsOrBroadcastInd
Publications Or Broadcast	$130,387	PublicationsOrBroadcastAmt
Grants Other Organizations	false	GrantsOtherOrganizationsInd
Direct Contact Legislators	Yes (true)	DirectContactLegislatorsInd
Direct Contact Legislators	$489,524	DirectContactLegislatorsAmt
Rallies Demonstrations	Yes (true)	RalliesDemonstrationsInd
Rallies Demonstrations	$218,281	RalliesDemonstrationsAmt
Other Activities	Yes (true)	OtherActivitiesInd
Other Activities	$1,424,000	OtherActivitiesAmt
Total Lobbying Expenditures	$2,481,864	TotalLobbyingExpendituresAmt
Not Described Section501c3	false	NotDescribedSection501c3Ind

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	SCHEDULE C, PART II-B, LINE 1	FormAndLineReferenceDesc
Explanation	LLS PARTICIPATES IN A NUMBER OF COALITIONS AND MEMBER ORGANIZATIONS, INCLUDING ALLIANCE FOR A STRONGER FDA, ALLIANCE FOR CHILDHOOD CANCER, CANCER LEADERSHIP COUNCIL, DEFENSE HEALTH RESEARCH CONSORTIUM, FRIENDS OF CANCER RESEARCH, NCSL FOUNDATION FOR STATE LEGISLATURES, ONE VOICE AGAINST CANCER, PARTNERSHIP TO PROTECT COVERAGE, PATIENT QUALITY OF LIFE COALITION, PUBLIC AFFAIRS COUNCIL, AND STATE ACCESS TO INNOVATIVE MEDICINES COALITION. EMPLOYEES IN THE LLS OFFICE OF PUBLIC POLICY WORK TO ADVANCE THE ORGANIZATIONS PUBLIC POLICY PRIORITIES, DOING SO WITH SUPPORT FROM LOBBYING FIRMS AND ADVISERS RETAINED BY LLS AND IN PARTNERSHIP WITH VOLUNTEER ADVOCATES. LLS VOLUNTEER ADVOCATES ENGAGE THEIR LAWMAKERS BY CONDUCTING LETTER-WRITING CAMPAIGNS, SHARING THEIR PERSONAL STORIES, AND CONDUCTING ONE-ON-ONE VISITS IN STATE CAPITOLS AND IN WASHINGTON, D.C. ALL WITH SUPPORT FROM THE LLS OFFICE OF PUBLIC POLICY.	ExplanationTxt

Schedule D IRS990ScheduleD

Field	Value	IRS element (for citing)
Collection Used Pub Exhibition	Yes (X)	CollectionUsedPubExhibitionInd
Solicited Assets Sale	false	SolicitedAssetsSaleInd

CY Endwmt Fund CYEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$7,381,460	BeginningYearBalanceAmt
Contributions	$1,129,903	ContributionsAmt
Investment Earnings Or Losses	-$913,685	InvestmentEarningsOrLossesAmt
Grants Or Scholarships	-$295,324	GrantsOrScholarshipsAmt
Administrative Expenses	-$14,061	AdministrativeExpensesAmt
End Year Balance	$7,288,293	EndYearBalanceAmt

CY Minus1 Yr Endwmt Fund CYMinus1YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$5,902,791	BeginningYearBalanceAmt
Contributions	$1,650	ContributionsAmt
Investment Earnings Or Losses	$1,726,314	InvestmentEarningsOrLossesAmt
Grants Or Scholarships	-$236,177	GrantsOrScholarshipsAmt
Administrative Expenses	-$13,118	AdministrativeExpensesAmt
End Year Balance	$7,381,460	EndYearBalanceAmt

CY Minus2 Yr Endwmt Fund CYMinus2YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$6,168,319	BeginningYearBalanceAmt
Investment Earnings Or Losses	-$8,812	InvestmentEarningsOrLossesAmt
Grants Or Scholarships	-$246,718	GrantsOrScholarshipsAmt
Administrative Expenses	-$9,998	AdministrativeExpensesAmt
End Year Balance	$5,902,791	EndYearBalanceAmt

CY Minus3 Yr Endwmt Fund CYMinus3YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$6,192,807	BeginningYearBalanceAmt
Investment Earnings Or Losses	$292,934	InvestmentEarningsOrLossesAmt
Grants Or Scholarships	-$304,999	GrantsOrScholarshipsAmt
Administrative Expenses	-$12,423	AdministrativeExpensesAmt
End Year Balance	$6,168,319	EndYearBalanceAmt

CY Minus4 Yr Endwmt Fund CYMinus4YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$5,897,377	BeginningYearBalanceAmt
Contributions	$200	ContributionsAmt
Investment Earnings Or Losses	$546,324	InvestmentEarningsOrLossesAmt
Grants Or Scholarships	-$237,896	GrantsOrScholarshipsAmt
Administrative Expenses	-$13,198	AdministrativeExpensesAmt
End Year Balance	$6,192,807	EndYearBalanceAmt

Field	Value	IRS element (for citing)
Prmnnt Endowment Balance EOY	0.54600	PrmnntEndowmentBalanceEOYPct
Term Endowment Balance EOY	0.45400	TermEndowmentBalanceEOYPct
Endowments Held Unrelated Org	false	EndowmentsHeldUnrelatedOrgInd
Endowments Held Related Org	false	EndowmentsHeldRelatedOrgInd

Leasehold Improvements LeaseholdImprovementsGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$1,214,662	OtherCostOrOtherBasisAmt
Depreciation	$866,323	DepreciationAmt
Book Value	$348,339	BookValueAmt

Equipment EquipmentGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$20,964,776	OtherCostOrOtherBasisAmt
Depreciation	$10,779,014	DepreciationAmt
Book Value	$10,185,762	BookValueAmt

Other Land Buildings OtherLandBuildingsGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$51,546	OtherCostOrOtherBasisAmt
Depreciation	$51,546	DepreciationAmt

Field	Value	IRS element (for citing)
Total Book Value Land Buildings	$10,534,101	TotalBookValueLandBuildingsAmt
Footnote Text	Yes (X)	FootnoteTextInd
Total Rev Etc Audited Fincl Stmt	$443,864,558	TotalRevEtcAuditedFinclStmtAmt
Net Unrealized Gains Invst	$1,356,633	NetUnrealizedGainsInvstAmt
Donated Services And Use Fclts	$3,262,633	DonatedServicesAndUseFcltsAmt
Other Revenue	$12,475,875	OtherRevenueAmt
Revenue Not Reported	$17,095,141	RevenueNotReportedAmt
Revenue Subtotal	$426,769,417	RevenueSubtotalAmt
Investment Expenses Not Incld	$227,787	InvestmentExpensesNotIncldAmt
Revenue Not Reported Fincl Stmt	$227,787	RevenueNotReportedFinclStmtAmt
Total Revenue Per Form990	$426,997,204	TotalRevenuePerForm990Amt
Tot Expns Etc Audited Fincl Stmt	$534,237,404	TotExpnsEtcAuditedFinclStmtAmt
Donated Services Use Fclts	$3,262,633	DonatedServicesUseFcltsAmt
Other Expenses Included	$12,580,164	OtherExpensesIncludedAmt
Expenses Not Reported	$15,842,797	ExpensesNotReportedAmt
Expenses Subtotal	$518,394,607	ExpensesSubtotalAmt
Investment Expenses Not Incld2	$227,787	InvestmentExpensesNotIncld2Amt
Expenses Not Rpt Fincl Stmt	$227,787	ExpensesNotRptFinclStmtAmt
Total Expenses Per Form990	$518,622,394	TotalExpensesPerForm990Amt

Supplemental Information Detail SupplementalInformationDetail (5 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
SCHEDULE D, PAGE 2, PART III, LINE 4	THE LLS COLLECTION IS OF PHOTOGRAPHS WHICH ARE USED FOR PUBLIC EXHIBITION AT FUNDRAISING EVENTS HELD TO SUPPORT LLS'S PROGRAMS.
SCHEDULE D, PAGE 2, PART V, LINE 4	LLS'S ENDOWMENTS ARE INTENDED TO FUND RESEARCH AS WELL AS SUPPORT LLS'S PUBLIC EDUCATION PROGRAMS.
SCHEDULE D, PAGE 3, PART X	LLS, LLSRP, AND LLSRF QUALIFY AS CHARITABLE ORGANIZATIONS AS DEFINED BY INTERNAL REVENUE CODE SECTION 501(C)(3) AND, ACCORDINGLY, ARE EXEMPT FROM FEDERAL INCOME TAXES UNDER INTERNAL REVENUE CODE SECTION 501(A). ADDITIONALLY, SINCE THESE ORGANIZATIONS ARE PUBLICLY SUPPORTED, CONTRIBUTIONS QUALIFY FOR THE MAXIMUM CHARITABLE CONTRIBUTION DEDUCTION UNDER THE INTERNAL REVENUE CODE. LLSC IS REGISTERED AS A CHARITABLE ORGANIZATION UNDER THE INCOME TAX ACT (CANADA) AND IS, THEREFORE, NOT SUBJECT TO INCOME TAXES IF CERTAIN DISBURSEMENT REQUIREMENTS ARE MET. LLS AND ITS RELATED ENTITIES RECOGNIZE THE EFFECT OF TAX POSITIONS ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT TO BE SUSTAINED. INCOME GENERATED FROM ACTIVITIES UNRELATED TO LLS'S EXEMPT PURPOSE IS SUBJECT TO TAX UNDER INTERNAL REVENUE CODE SECTION 511. THERE WERE NOT ENTITIES THAT RECOGNIZED UNRELATED BUSINESS INCOME TAX LIABILITY FOR THE YEARS ENDED JUNE 30, 2022 AND JUNE 30, 2021.
SCHEDULE D, PAGE 4, PART XI, LINE 2D	LLS CANADA REVENUE 12,475,875
SCHEDULE D, PAGE 4, PART XII, LINE 2D	LLS CANADA EXPENSES 12,580,164

Schedule F IRS990ScheduleF

Field	Value	IRS element (for citing)
Grant Records Maintained	Yes (true)	GrantRecordsMaintainedInd

Account Activities Outside US AccountActivitiesOutsideUSGrp (6 entries)

RegionRegionTxt	OfficesOfficesCnt	Type Of Activities ConductedTypeOfActivitiesConductedTxt	Specific Services ProvidedSpecificServicesProvidedTxt	Region Total ExpendituresRegionTotalExpendituresAmt
NORTH AMERICA	1	RESEARCH FUNDING	RESEARCH GRANTS	$618,500
EUROPE		RESEARCH FUNDING	RESEARCH GRANTS	$5,143,371
CENTRAL AMERICA & CARIBBEAN		INVESTMENTS	INVESTMENTS	$8,391,601
MIDDLE EAST & NORTH AFRICA		RESEARCH FUNDING	RESEARCH GRANTS	$120,000
EAST ASIA & THE PACIFIC		RESEARCH FUNDING	RESEARCH GRANTS	$1,756,822
EUROPE		INVESTMENTS	INVESTMENTS	$464,018

Field	Value	IRS element (for citing)
Subtotal Offices	1	SubtotalOfficesCnt
Total Office	1	TotalOfficeCnt
Subtotal Spent	$16,494,312	SubtotalSpentAmt
Total Spent	$16,494,312	TotalSpentAmt

Grants To Org Outside US GrantsToOrgOutsideUSGrp (24 entries)

RegionRegionTxt	Purpose Of GrantPurposeOfGrantTxt	Cash GrantCashGrantAmt	Manner Of Cash DisbursementMannerOfCashDisbursementTxt	Valuation Method UsedValuationMethodUsedDesc
NORTH AMERICA	RESEARCH GRANT	$150,000	WIRE PAYMENT	ACCRUAL
EUROPE	RESEARCH GRANT	$600,000	WIRE PAYMENT	ACCRUAL
EUROPE	RESEARCH GRANT	$200,000	WIRE PAYMENT	ACCRUAL
EUROPE	RESEARCH GRANT	$99,962	WIRE PAYMENT	ACCRUAL
EUROPE	RESEARCH GRANT	$10,000	WIRE PAYMENT	ACCRUAL
EAST ASIA AND PACIFIC	RESEARCH GRANT	$250,000	WIRE PAYMENT	ACCRUAL
EAST ASIA AND PACIFIC	RESEARCH GRANT	$1,031,822	WIRE PAYMENT	ACCRUAL
EAST ASIA AND PACFIC	RESEARCH GRANT	$350,000	WIRE PAYMENT	ACCRUAL
NORTH AMERICA	RESEARCH GRANT	$318,500	WIRE PAYMENT	ACCRUAL
MIDDLE EAST AND NORTH AFRICA	RESEARCH GRANT	$120,000	WIRE PAYMENT	ACCRUAL
EAST ASIA AND PACIFIC	RESEARCH GRANT	$125,000	WIRE PAYMENT	ACCRUAL
NORTH AMERICA	RESEARCH GRANT	$150,000	WIRE PAYMENT	ACCRUAL
EUROPE	RESEARCH GRANT	$250,000	WIRE PAYMENT	ACCRUAL
EUROPE	RESEARCH GRANT	$125,000	WIRE PAYMENT	ACCRUAL
EUROPE	RESEARCH GRANT	$250,000	WIRE PAYMENT	ACCRUAL
EUROPE	RESEARCH GRANT	$399,995	WIRE PAYMENT	ACCRUAL
EUROPE	RESEARCH GRANT	$249,977	WIRE PAYMENT	ACCRUAL
EUROPE	RESEARCH GRANT	$125,000	WIRE PAYMENT	ACCRUAL
EUROPE	RESEARCH GRANT	$193,182	WIRE PAYMENT	ACCRUAL
EUROPE	RESEARCH GRANT	$63,221	WIRE PAYMENT	ACCRUAL
EUROPE	RESEARCH GRANT	$114,123	WIRE PAYMENT	ACCRUAL
EUROPE	THERAPY ACCELERATION	$1,310,105	WIRE PAYMENT	FMV
EUROPE	THERAPY ACCELERATION	$250,000	WIRE PAYMENT	FMV
EUROPE	RESEARCH GRANT	$902,806	WIRE	FMV

Field	Value	IRS element (for citing)
Total Other Org	24	TotalOtherOrgCnt
Transfer To Foreign Corp	Yes (true)	TransferToForeignCorpInd
Interest In Foreign Trust	false	InterestInForeignTrustInd
Foreign Corp Ownership	Yes (true)	ForeignCorpOwnershipInd
Passive Foreign Investmest Co	Yes (true)	PassiveForeignInvestmestCoInd
Foreign Partnership	false	ForeignPartnershipInd
Boycott Countries	false	BoycottCountriesInd

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDesc

ExplanationExplanationTxt

SCHEDULE F, PAGE 1, PART I, LINE 2

FIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS, EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL LLS RECEIVES AND APPROVES THE DELINQUENT REPORT. THE ACCOUNTING METHOD UTILIZED FOR GRANTS REPORTED ON PART II IS THE ACCRUAL METHOD AS CONSISTENT WITH BOOKS AND RECORDS.

SCHEDULE F, PAGE 1, PART I, LINE 3

NORTH AMERICA 618,500 0 EUROPE 5,143,371 0 CENTRAL AMERICA & CARIBBEAN 0 8,391,601 MIDDLE EAST & NORTH AFRICA 120,000 0 EAST ASIA & THE PACIFIC 1,756,822 0 EUROPE 0 464,018

Schedule G IRS990ScheduleG

Field	Value	IRS element (for citing)
Mail Solicitations	Yes (X)	MailSolicitationsInd
Email Solicitations	Yes (X)	EmailSolicitationsInd
Phone Solicitations	Yes (X)	PhoneSolicitationsInd
In Person Solicitations	Yes (X)	InPersonSolicitationsInd
Solicitation Of Non Govt Grants	Yes (X)	SolicitationOfNonGovtGrantsInd
Solicitation Of Govt Grants	Yes (X)	SolicitationOfGovtGrantsInd
Special Fundraising Events	Yes (X)	SpecialFundraisingEventsInd
Agrmt Prof Fundraising Acty	Yes (true)	AgrmtProfFundraisingActyInd

Fundraiser Activity Info FundraiserActivityInfoGrp (2 entries)

Address Line1USAddress/AddressLine1Txt	CityUSAddress/CityNm	State AbbreviationUSAddress/StateAbbreviationCd	ZIPUSAddress/ZIPCd	ActivityActivityTxt	Fundraiser Control Of FundsFundraiserControlOfFundsInd	Retained By ContractorRetainedByContractorAmt	Net To OrganizationNetToOrganizationAmt
RESOURCE ONE
2900 EAST APACHE STREET	TULSO	OK	74110	DIRECT MAI	false	$4,883,318	-$4,883,318
THOMPSON HABIB & DENISON
80 HAYDEN AVENUE SUITE 300	LEXINGTON	MA	02421	DIRECT MAI	false	$670,969	-$670,969

Field	Value	IRS element (for citing)
Total Retained By Contractors	$5,554,287	TotalRetainedByContractorsAmt
Total Net To Organization	-$5,554,287	TotalNetToOrganizationAmt
All States	All States	AllStatesCd

Fundraising Event Information FundraisingEventInformationGrp

Field	Value	IRS element (for citing)
Event1	STUDENT VISIONA	Event1Nm
Gross Receipts Event1	$3,702,932	GrossReceiptsEvent1Amt
Charitable Contri Event1	$3,531,242	CharitableContriEvent1Amt
Gross Revenue Event1	$171,690	GrossRevenueEvent1Amt
Non Cash Prizes Event1	$9,215	NonCashPrizesEvent1Amt
Rent Facility Costs Event1	$161,718	RentFacilityCostsEvent1Amt
Food And Beverage Event1	$889	FoodAndBeverageEvent1Amt
Other Direct Expenses Event1	$362	OtherDirectExpensesEvent1Amt
Event2	LAKE TAHOE BIKE	Event2Nm
Gross Receipts Event2	$3,491,630	GrossReceiptsEvent2Amt
Charitable Contri Event2	$3,298,234	CharitableContriEvent2Amt
Gross Revenue Event2	$193,396	GrossRevenueEvent2Amt
Rent Facility Costs Event2	$18,104	RentFacilityCostsEvent2Amt
Food And Beverage Event2	$48,991	FoodAndBeverageEvent2Amt
Entertainment Event2	$21,164	EntertainmentEvent2Amt
Other Direct Expenses Event2	$260,674	OtherDirectExpensesEvent2Amt
Other Events Total	323	OtherEventsTotalCnt
Gross Receipts Other Events	$165,035,600	GrossReceiptsOtherEventsAmt
Charitable Contri Other Events	$152,112,648	CharitableContriOtherEventsAmt
Gross Revenue Other Events	$12,922,952	GrossRevenueOtherEventsAmt
Non Cash Prizes Other Events	$2,032,811	NonCashPrizesOtherEventsAmt
Rent Fclty Costs Other Events	$7,616,287	RentFcltyCostsOtherEventsAmt
Food And Beverage Other Events	$3,103,115	FoodAndBeverageOtherEventsAmt
Entertainment Other Events	$353,146	EntertainmentOtherEventsAmt
Oth Direct Expnss Other Events	$1,378,491	OthDirectExpnssOtherEventsAmt
Gross Receipts Total	$172,230,162	GrossReceiptsTotalAmt
Charitable Contributions Tot	$158,942,124	CharitableContributionsTotAmt
Gross Revenue Total Events	$13,288,038	GrossRevenueTotalEventsAmt
Non Cash Prizes Total Events	$2,042,026	NonCashPrizesTotalEventsAmt
Rent Fclty Costs Total Events	$7,796,109	RentFcltyCostsTotalEventsAmt
Food And Beverage Total Events	$3,152,995	FoodAndBeverageTotalEventsAmt
Entertainment Total Events	$374,310	EntertainmentTotalEventsAmt
Oth Direct Expnss Total Events	$1,639,527	OthDirectExpnssTotalEventsAmt
Direct Expense Summary Events	$15,004,967	DirectExpenseSummaryEventsAmt
Net Income Summary	-$1,716,929	NetIncomeSummaryAmt

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	SCHEDULE G, PART IV	FormAndLineReferenceDesc
Explanation	SCHEDULE G PART I, LINE 2B LLS USED RESOURCE ONE AND THOMPSON HABIB, & DENISON FOR IT'S NATIONAL COMMUNITY CAMPAIGN AND DIRECT MAIL PROGRAMS. SCHEDULE G PART II - LINE 2 CONTRIBUTIONS REPRESENT THE CASH DONATIONS IN EXCESS OF FAIR MARKET VALUE BENEFITS PROVIDED TO THE DONOR.	ExplanationTxt

Schedule I IRS990ScheduleI

Field	Value	IRS element (for citing)
Grant Records Maintained	Yes (true)	GrantRecordsMaintainedInd

Recipient Table RecipientTable (74 entries)

Address Line1USAddress/AddressLine1Txt	Address Line2USAddress/AddressLine2Txt	CityUSAddress/CityNm	State AbbreviationUSAddress/StateAbbreviationCd	ZIPUSAddress/ZIPCd	Recipient EINRecipientEIN	IRC SectionIRCSectionDesc	Cash GrantCashGrantAmt	Valuation Method UsedValuationMethodUsedDesc	Purpose Of GrantPurposeOfGrantTxt
ALBERT EINSTEIN COLLEGE OF MEDICINE
RESEARCH FINANCE	1300 MORRIS PARK AVE BELFER 1108	BRONX	NY	10461	472209056	3	$157,000	ACCRUAL	RESEARCH GRANT
ATRIUM HEALTH FOUNDATION
208 EAST BOULEVARD	ATTN ELECTA MCPHERSON	CHARLOTTE	NC	28203	566060481	3	$19,565	ACCRUAL	RESEARCH GRANT
BAYLOR COLLEGE OF MEDICINE
BAYLOR COLLEGE OF MEDICINE	P O BOX 301207	DALLAS	TX	753031207	741613878	3	$1,914,672	ACCRUAL	RESEARCH GRANT
BE THE MATCH FOUNDATION
500 N 5TH STREET		MINNEAPOLIS	MN	55401	411704734	3	$300,000	ACCRUAL	RESEARCH GRANT
BECKMAN RESEARCH INSTITUTE OF THE C
1500 EAST DUARTE ROAD	ATTN VALERIE BINGHAM	DUARTE	CA	91010	953432210	3	$1,705,029	ACCRUAL	RESEARCH GRANT
BOARD OF TRUSTEES OF THE LELAND STA
STANFORD UNIVERSITY LOCKBOX		SAN FRANCISCO	CA	941444253	941156365	3	$1,577,466	ACCRUAL	RESEARCH GRANT
BRIGHAM AND WOMENS HOSPITAL
RESEARCH	PO BOX 3149	BOSTON	MA	022413149	042312909	3	$194,008	ACCRUAL	RESEARCH GRANT
CINCINNATI CHILDREN'S HOSPITAL MEDI
3333 BURNET AVENUE ML 4900		CINCINATTI	OH	45229	310833936	3	$741,675	ACCRUAL	RESEARCH GRANT
CLEVELAND CLINIC FOUNDATION
9500 EUCLID AVENUE		CLEVELAND	OH	44195	340714585	3	$410,000	ACCRUAL	RESEARCH GRANT
DANA-FARBER CANCER INSTITUTE
RESEARCH ACCOUNTING MAIL STOP BP43	450 BROOKLINE AVENUE	BOSTON	MA	02215	042263040	3	$2,864,999	ACCRUAL	RESEARCH GRANT
EMORY UNIVERSITY
EMORY UNIVERSITY	PO BOX 935084	ATLANTA	GA	311935084	582137993	3	$1,499,219	ACCRUAL	RESEARCH GRANT
FRED HUTCHINSON CANCER RESEARCH CEN
1100 FAIRVIEW AVENUE NORTH J6-300		SEATTLE	WA	981091024	237156071	3	$1,972,000	ACCRUAL	RESEARCH GRANT
H LEE MOFFITT CANCER CENTER & RESE
PO BOX 742801		ATLANTA	GA	303742801	593238634	3	$61,919	ACCRUAL	RESEARCH GRANT
HACKENSACK MERIDIAN HEALTH
40 PROSPECT AVENUE	ATTN DAVID CANDELMO OFFICE OF RE	HACKENSACK	NJ	07601	010649794	3	$99,000	ACCRUAL	RESEARCH GRANT
ICAHN SCHOOL OF MEDICINE AT MOUNT S
ATTN RAJ APPAVU	ONE GUSTAVE L LEVY PLACE BOX 350	NEW YORK	NY	10029	136171197	3	$612,750	ACCRUAL	RESEARCH GRANT
INDIANA UNIVERSITY
OFFICE OF RESEARCH ADMINISTRATION	PO BOX 78000	DETROIT	MI	482780867	356018940	3	$18,822	ACCRUAL	RESEARCH GRANT
INTERNATIONAL WALDENSTROM'S MACROGL
6144 CLARK CENTER AVE		SARASOTA	FL	34238	541784426	3	$100,000	ACCRUAL	RESEARCH GRANT
JOAN & SANFORD I WEILL MEDICAL COL
575 LEXINGTON AVE 9TH FL	ATTN MELISSA PARAY	NEW YORK	NY	10022	131623978	3	$1,332,500	ACCRUAL	RESEARCH GRANT
MASSACHUSETTS GENERAL HOSPITAL
MGH RESEARCH FINANCE	PO BOX 414876	BOSTON	MA	022414876	041564655	3	$1,131,249	ACCRUAL	RESEARCH GRANT
MAYO CLINIC ROCHESTER
MAYO CLINIC RESEARCH	PO BOX 860334	MINNEAPOLIS	MN	554860334	416011702	3	$275,000	ACCRUAL	RESEARCH GRANT
MYELOPROLIFERATIVE NEOPLASMS RESEAR
180 N MICHIGAN AVENUE	SUITE 1870	CHICAGO	IL	60601	364330967	3	$200,000	ACCRUAL	RESEARCH GRANT
NEW YORK UNIVERSITY SCHOOL OF MEDIC
SPONSORED PROGRAMS	PO BOX 415026	BOSTON	MA	022414150	135562308	3	$135,515	ACCRUAL	RESEARCH GRANT
NORTHWESTERN UNIVERSITY
ACCOUNTING SERVICES FOR RESEARCH	633 CLARK - ROOM G547	EVANSTON	IL	60208	362167817	3	$135,500	ACCRUAL	RESEARCH GRANT
OSU FOUNDATION
1960 KENNY ROAD 4TH FLOOR		COLUMBUS	OH	432101016	316025986	3	$600,000	ACCRUAL	RESEARCH GRANT
PERELMAN SCHOOL OF MEDICINE AT THE
OFFICE OF RESEARCH SERVICES	3451 WALNUT STREET FRANKLIN BLDG P-	PHILADELPHIA	PA	191046205	231352685	3	$869,057	ACCRUAL	RESEARCH GRANT
REGENTS OF THE UNIVERSITY OF MICHIG
BOX 223131		PITTSBURGH	PA	152512131	386006309	3	$660,000	ACCRUAL	RESEARCH GRANT
ROCKEFELLER UNIVERSITY
1230 YORK AVENUE BOX 82		NEW YORK	NY	10021	131624158	3	$10,000	ACCRUAL	RESEARCH GRANT
SEATTLE CHILDREN'S HOSPITAL
4800 SAND POINT WAY NE		SEATTLE	WA	98105	911156519	3	$74,859	ACCRUAL	RESEARCH GRANT
SLOAN KETTERING INSTITUTE FOR CANCE
SLOAN KETTERING INSTITUTE FOR CANCE	MSKC FINANCE GENERAL POST OFFICE PO	NEW YORK	NY	10087	131924236	3	$1,727,771	ACCRUAL	RESEARCH GRANT
ST JUDE CHILDREN'S RESEARCH HOSPIT
PO BOX 1000 DEPT 949		MEMPHIS	TN	381480949	620646012	3	$300,500	ACCRUAL	RESEARCH GRANT
TEMPLE UNIVERSITY
RESEARCH ACCOUNTING SERVICES	PO BOX 824242	PHILADELPHIA	PA	191824242	231365971	3	$200,000	ACCRUAL	RESEARCH GRANT
THE CHILDREN'S HOSPITAL OF PHILADEL
LOCKBOX 1457	PO BOX 8500	PHILADELPHIA	PA	191781457	231352166	3	$246,150	ACCRUAL	RESEARCH GRANT
THE JACKSON LABORATORY
600 MAIN STREET		BAR HARBOR	ME	046091523	010211513	3	$30,000	ACCRUAL	RESEARCH GRANT
THE JOHNS HOPKINS UNIVERSITY SCHOOL
JOHNS HOPKINS UNIVERSITY CENTRAL LO	12529 COLLECTIONS CENTER DRIVE	CHICAGO	IL	60693	520595110	3	$660,000	ACCRUAL	RESEARCH GRANT
THE OHIO STATE UNIVERSITY
1960 KENNY ROAD 4TH FLOOR	ATTN RICHARD BRADBURY	COLUMBUS	OH	432101016	316025986	3	$579,440	ACCRUAL	RESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
9500 GILMAN DRIVE MC 0009		LA JOLLA	CA	920930009	956006144	3	$620,000	ACCRUAL	RESEARCH GRANT
THE REGENTS OF THE UNIVERSITY OF CA
UCSF MAIN DEPOSITORY		LOS ANGELES	CA	900744872	946036493	3	$250,000	ACCRUAL	RESEARCH GRANT
THE TRUSTEES OF COLUMBIA UNIVERSITY
SPONSORED PROJECTS FINANCE		NEW YORK	NY	100879789	135598093	3	$914,500	ACCRUAL	RESEARCH GRANT
THE TRUSTEES OF THE UNIVERSITY OF P
OFFICE OF RESEARCH SERVICES	3451 WALNUT STREET FRANKLIN BLDG P	PHILADELPHIA	PA	191046205	231352685	3	$1,609,600	ACCRUAL	RESEARCH GRANT
THE UNIVERSITY OF ALABAMA AT BIRMIN
1530 3RD AVENUE SOUTH SUITE 1170		BIRMINGHAM	AL	352940111	636005396	3	$500,000	ACCRUAL	RESEARCH GRANT
THE UNIVERSITY OF CHICAGO
5841 S MARYLAND AVE MC6092		CHICAGO	IL	60637	362177139	3	$436,999	ACCRUAL	RESEARCH GRANT
THE UNIVERSITY OF NORTH CAROLINA AT
OFFICE OF SPONSORED RESEARCH IN CA	PO BOX 402420	ATLANTA	GA	303842420	566001393	3	$303,000	ACCRUAL	RESEARCH GRANT
THE UNIVERSITY OF TEXAS MD ANDERSON
ATTN GRANTS AND CONTRACTS	PO BOX 4266	HOUSTON	TX	772104266	746001118	3	$1,947,088	ACCRUAL	RESEARCH GRANT
THE UNIVERSITY OF TEXAS SOUTHWESTER
PO BOX 841753		DALLAS	TX	752841753	756002868	3	$315,500	ACCRUAL	RESEARCH GRANT
THE UNIVERSITY OF UTAH
201 S PRESIDENTS CIRCLE RM 145	ACCOUNTS PAYABLE	SALT LAKE CITY	UT	841129003	876000525	3	$5,500	ACCRUAL	RESEARCH GRANT
UNIVERSITY OF CALIFORNIA IRVINE
OFFICE OF RESEARCH ADMINISTRATION	300 UNIVERSITY TOWER UNIVERSITY OF	IRVINE	CA	926977600	952540117	3	$10,000	ACCRUAL	RESEARCH GRANT
UNIVERSITY OF COLORADO DENVER ANSC
ANSCHUTZ MEDICAL CAMPUS BLDG 500	PO BOX 6508	AURORA	CO	80045	846000555	3	$1,301,250	ACCRUAL	RESEARCH GRANT
UNIVERSITY OF COLORADO-DENVER
12700 E 19TH AVENUE		AURORA	CO	80045	846000555	3	$50,000	ACCRUAL	RESEARCH GRANT
UNIVERSITY OF FLORIDA
33 TIGERT HALL	P O BOX 113001	GAINESVILLE	FL	326113001	596002052	3	$2,060,331	ACCRUAL	RESEARCH GRANT
UNIVERSITY OF MIAMI
OFFICE OF RESEARCH ADMINISTRATION	PO BOX 405803	ATLANTA	GA	303845803	590624458	3	$696,891	ACCRUAL	RESEARCH GRANT
UNIVERSITY OF NOTRE DAME
511 MAIN BUILDING		NOTRE DAME	IN	46556	350868188	3	$10,000	ACCRUAL	RESEARCH GRANT
UNIVERSITY OF SOUTHERN CALIFORNIA
SPONSORED PROJECTS ACCOUNTING	FILE NO 52095	LOS ANGELES	CA	90089	951642394	3	$55,000	ACCRUAL	RESEARCH GRANT
UNIVERSITY OF VIRGINIA
ATTN OFFICE OF SPONSORED PROGRAMS	PO BOX 400195	CHARLOTTESVILLE	VA	229044195	237173411	3	$115,500	ACCRUAL	RESEARCH GRANT
VAN ANDEL RESEARCH INSTITUTE
333 BOSTWICK AVE NE		GRAND RAPIDS	MI	49503	522000820	3	$120,000	ACCRUAL	RESEARCH GRANT
VANDERBILT UNIVERSITY MEDICAL CENTE
DEPT OF FINANCE ATTN STEVE TODD	DEPT 1236 PO BOX 121236	DALLAS	TX	75312	620476822	3	$881,576	ACCRUAL	RESEARCH GRANT
WASHINGTON UNIVERSITY IN ST LOUIS
CAMPUS BOX 1034	700 ROSEDALE AVENUE	ST LOUIS	MO	63112	430653611	3	$467,000	ACCRUAL	RESEARCH GRANT
WASHINGTON UNIVERSITY SCHOOL OF MED
SPONSORED PROJECTS ACCOUNTING	700 ROSEDALE AVENUE CAMPUS BOX 1034	ST LOUIS	MO	631121408	430653611	3	$829,998	ACCRUAL	RESEARCH GRANT
WESTERN INSTITUTE FOR VETERANS RESE
PO BOX 58719		SALT LAKE CITY	UT	84158	870470748	3	$431,963	ACCRUAL	RESEARCH GRANT
YALE UNIVERSITY
OFFICE OF SPONSORED PROJECTS	PO BOX 1873	NEW HAVEN	CT	065201873	060646973	3	$562,500	ACCRUAL	RESEARCH GRANT
TULANE UNIVERSITY HEALTH SCIENCES C
1430 TULANE AVE EP15		NEW ORLEANS	LA	70112	720423889	3	$123,385	ACCRUAL	RESEARCH GRANT
CITY OF HOPE NATIONAL MEDICAL CENTE
1500 EAST DUARTE ROAD		DUARTE	CA	910103000	951683875	3	$400,000	ACCRUAL	RESEARCH GRANT
RUTGERS UNIVERSITY
3 RUTGERS PLAZA		NEW BRUNSWICK	NJ	08901	226001086	3	$120,000	ACCRUAL	RESEARCH GRANT
OREGON HEALTH & SCIENCE UNIVERSITY
3181 SW SAM JACKSON PARK ROAD	MAIL CODE L106	PORTLAND	OR	97239	237083114	3	$120,000	ACCRUAL	RESEARCH GRANT
INSTITUTE FOR CANCER RESEARCH DBA
333 COTTMAN AVENUE		PHILADELPHIA	PA	191112434	232003072	3	$120,000	ACCRUAL	RESEARCH GRANT
RHODE ISLAND HOSPITAL
593 EDDY STREET ALDRICH 3-317		PROVIDENCE	RI	02903	050258954	3	$125,000	ACCRUAL	RESEARCH GRANT
MEDICAL COLLEGE OF WISCONSIN
8701 W WATERTOWN PLANK RD		MILWAUKEE	WI	53226	390806261	3	$125,000	ACCRUAL	RESEARCH GRANT
DUKE UNIVERSITY
DUKE UNIVERSITY ACCOUNTS RECEIVABLE	PO BOX 602651	CHARLOTTE	NC	282602651	560532129	3	$124,954	ACCRUAL	RESEARCH GRANT
MAYO CLINIC ARIZONA
MAYO CLINIC RESEARCH	PO BOX 860334	MINNEAPOLIS	MN	554860334	860800150	3	$200,000	ACCRUAL	RESEARCH GRANT
CASE WESTERN RESERVE UNIVERSITY
OFFICE OF RESEARCH ADMINISTRATION	10900 EUCLID AVENUE-NORD HALL SUITE	CLEVELAND	OH	441067037	341018992	3	$125,000	ACCRUAL	RESEARCH GRANT
PRESIDENT & FELLOWS OF HARVARD COLL
PO BOX 415649		BOSTON	MA	02241	042103580	3	$499,615	ACCRUAL	RESEARCH GRANT
REGENTS OF THE UNIVERSITY OF MINNES
NW5957	PO BOX 1450	MINNEAPOLIS	MN	554855957	416007513	3	$250,000	ACCRUAL	RESEARCH GRANT
ABINTUS BIO
10355 SCIENCE CENTER DR	250	SAN DIEGO	CA	92121	844349617		$250,000	FMV	THERAPY ACCELERATION
IMMUNE -ONC THERAPEUTICS INC
2431 ALOMA AVE	124	WINTER PARK	FL	32792	593226705		$1,500,000	FMV	THERAPY ACCELERATION
IMMUNITAS
830 WINTER ST		WALTHAM	MA	02451	842813217		$500,000	FMV	THERAPY ACCELERATION

Field	Value	IRS element (for citing)
Total501c3 Org	71	Total501c3OrgCnt
Total Other Org	3	TotalOtherOrgCnt

Grants Other Asst To Indiv In US GrantsOtherAsstToIndivInUSGrp (11 entries)

Grant TypeGrantTypeTxt	RecipientRecipientCnt	Cash GrantCashGrantAmt
COPAY ASSISTANCE CLL	7168	$49,165,474
COPAY ASSISTANCE LYMPHOMA	3768	$11,818,318
COPAY ASSISTANCE MDS	3012	$15,863,866
COPAY ASSISTANCE MYELOMA	15583	$117,657,639
COPAY ASSISTANCE MANTEL	1704	$11,647,828
COPAY ASSISTANCE WALDENST	2178	$13,256,872
COPAY ASSISTANCE ALL	85	$425,000
COPAY ASSISTANCE AML	3338	$16,657,899
COPAY ASSISTANCE CML	13	$26,000
PATIENT TRAVEL ASSISTANC	11486	$5,595,139
PATIENT AID	27168	$8,251,869

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	SCHEDULE I, PAGE 1, PART I, LINE 2	FormAndLineReferenceDesc
Explanation	FIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS, EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL LLS RECEIVES AND APPROVES THE DELINQUENT REPORT. PATIENT FINANCIAL AID: THE LEUKEMIA AND LYMPHOMA SOCIETY (LLS) REGULARLY RECEIVES CALLS FROM PATIENTS WHO CANNOT MOVE FORWARD WITH THEIR POTENTIALLY LIFE-SAVING TREATMENTS BECAUSE THEY CANNOT AFFORD TO PAY FOR MANY EXPENSES RELATED TO THEIR TREATMENT. SOMETIMES PATIENTS HAVE TO CHOOSE BETWEEN BASIC NEEDS SUCH AS FOOD OR SHELTER AND THEIR HEALTH CARE TREATMENT EXPENSES. IN AN EFFORT TO ALLEVIATE SUCH HARDSHIPS, LLS HAS ESTABLISHED A PATIENT FINANCIAL AID PROGRAM THAT PROVIDES APPLICANTS, WHO RESIDE IN THE US AND HAVE A BLOOD CANCER DIAGNOSIS, A ONE-TIME ANNUAL STIPEND TO HELP DEFER SOME OF THESE EXPENSES. LLS ROUTINELY CONDUCTS AN OPERATIONAL AUDIT VERIFYING APPLICANTS ARE IN COMPLIANCE WITH PROGRAM GUIDELINES AND PROGRAM CRITERIA. CO-PAY ASSISTANCE: PATIENT APPLICATIONS ARE PROCESSED ON A FIRST COME, FIRST SERVED BASIS. ELIGIBLE PATIENTS MUST RESIDE IN THE UNITED STATES OR PUERTO RICO, HAVE A PROGRAM COVERED BLOOD CANCER DIAGNOSIS CONFIRMED BY A PHYSICIAN, MAINTAIN MEDICAL/PRESCRIPTION INSURANCE AND HAVE HOUSEHOLD INCOME AT OR BELOW 500% OF THE US FEDERAL POVERTY LEVEL AS ADJUSTED BY HOUSEHOLD SIZE AND COST OF LIVING INDEX. PATIENTS MUST PROVIDE PROOF OF INSURANCE AND INCOME. QUALIFYING PATIENTS ARE APPROVED FOR A TWELVE MONTH COVERAGE PERIOD. PATIENT TRAVEL ASSISTANCE: THE LEUKEMIA AND LYMPHOMA SOCIETY (LLS) REGULARLY RECEIVES CALLS FROM PATIENTS WHO CANNOT MOVE FORWARD WITH THEIR POTENTIALLY LIFE-SAVING TREATMENTS BECAUSE THEY CANNOT AFFORD TO PAY FOR TRANSPORTATION TO GET TO THEIR PROVIDERS, E.G. DOCTORS, HOSPITALS, TRANSPLANT CENTERS, AND RESEARCH OR CLINICAL TRIAL CENTERS. SOMETIMES PATIENTS HAVE TO TRAVEL OUT-OF-STATE TO GET THEIR PRESCRIBED AND RECOMMENDED TREATMENTS, OFTENTIMES RESULTING IN PATIENTS HAVING TO CHOOSE BETWEEN BASIC NEEDS SUCH AS FOOD OR SHELTER AND THEIR HEALTH CARE. IN AN EFFORT TO ALLEVIATE SUCH HARDSHIPS, LLS ESTABLISHED THE TRAVEL ASSISTANCE PROGRAM WHICH PROVIDES APPLICANTS, WHO ARE US CITIZENS OR PERMANENT RESIDENTS, HAVE AN ANNUAL INCOME AT OR BELOW 500% OF THE FEDERAL POVERTY LEVEL (FPL) AND HAVE A CONFIRMED BLOOD CANCER DIAGNOSIS, A ONE-TIME ANNUAL STIPEND TO HELP DEFER SOME OF THESE EXPENSES. LLS ROUTINELY CONDUCTS AN OPERATIONAL AUDIT VERIFYING APPLICANTS ARE IN COMPLIANCE WITH PROGRAM GUIDELINES AND PROGRAM CRITERIA.	ExplanationTxt

Schedule J IRS990ScheduleJ

Field	Value	IRS element (for citing)
Compensation Committee	Yes (X)	CompensationCommitteeInd
Independent Consultant	Yes (X)	IndependentConsultantInd
Form990 Of Other Organizations	Yes (X)	Form990OfOtherOrganizationsInd
Compensation Survey	Yes (X)	CompensationSurveyInd
Board Or Committee Approval	Yes (X)	BoardOrCommitteeApprovalInd
Severance Payment	false	SeverancePaymentInd
Supplemental Nonqual Rtr Plan	false	SupplementalNonqualRtrPlanInd
Equity Based Comp Arrngm	false	EquityBasedCompArrngmInd
Comp Based On Revenue Of Flng Org	false	CompBasedOnRevenueOfFlngOrgInd
Comp Bsd On Rev Related Orgs	false	CompBsdOnRevRelatedOrgsInd
Comp Bsd Net Earns Flng Org	false	CompBsdNetEarnsFlngOrgInd
Comp Bsd Net Earns Rltd Orgs	false	CompBsdNetEarnsRltdOrgsInd
Any Non Fixed Payments	Yes (true)	AnyNonFixedPaymentsInd
Initial Contract Exception	false	InitialContractExceptionInd

Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (9 entries)

TitleTitleTxt	Base Compensation Filing OrgBaseCompensationFilingOrgAmt	Bonus Filing OrganizationBonusFilingOrganizationAmount	Other Compensation Filing OrgOtherCompensationFilingOrgAmt	Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt	Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt	Total Compensation Filing OrgTotalCompensationFilingOrgAmt
LOUIS J DEGENNARO
PRESIDENT & CEO	$708,367	$281,807	$21,012	$21,688	$29,516	$1,062,390
GWEN NICHOLS MD
EVP CHIEF MED OFFICE	$436,575	$147,258	$25,962	$14,444	$29,346	$653,585
TROY DUNMIRE
EVP CHIEF OPER OFFIC	$447,424	$144,589	$1,443	$14,516	$10,420	$618,392
GORDON MILLER JR
EVP CHIEF FIN OFFICE	$363,635	$117,372	$1,771	$22,281	$33,666	$538,725
DALE NISSENBAUM
EVP GEN COUNSEL	$372,606	$119,073	$1,798	$5,510	$13,816	$512,803
COKER POWELL
SVP CHIEF DEVELOPMNT	$334,633	$85,000	$20,320	$22,271	$43,532	$505,756
TOM OSGOOD
EVP CHIEF HR	$327,515	$105,621	$4,533	$16,050	$15,351	$469,070
VANESSA WHITE
SVP CHIEF ADV OFF	$357,849	$65,000	$1,212	$15,422	$24,274	$463,757
LEE M GREENBERGER
SVP CHIEF SCIEN OFFI	$316,120	$55,304	$12,808	$26,167	$39,916	$450,315

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	SCHEDULE J, PAGE 1, PART I, LINE 7	FormAndLineReferenceDesc
Explanation	LLS AWARDS NON-FIXED PAYMENTS SUCH AS BONUSES ON A DISCRETIONARY BASIS TIED TO THE EMPLOYEE PERFORMANCE AND ORGANIZATION TARGETS. THE NAMES OF EMPLOYEES AND THE AMOUNTS THAT WERE PAID ARE FOUND ON SCHEDULE J, PAGE 2, PART II, COL (B) (II). IN FY 22, LLS PAID BONUSES RELATED TO BOTH FY20 AND FY21 RESULTS.	ExplanationTxt

Schedule M IRS990ScheduleM

Securities Publicly Traded SecuritiesPubliclyTradedGrp

Field	Value	IRS element (for citing)
Non Cash Checkbox	Yes (X)	NonCashCheckboxInd
Contribution	181	ContributionCnt
Noncash Contributions Rpt F990	$1,729,949	NoncashContributionsRptF990Amt
Method Of Determining Revenues	FAIR MARKET VALUE	MethodOfDeterminingRevenuesTxt

Food Inventory FoodInventoryGrp

Field	Value	IRS element (for citing)
Non Cash Checkbox	Yes (X)	NonCashCheckboxInd
Contribution	8	ContributionCnt
Noncash Contributions Rpt F990	$37,250	NoncashContributionsRptF990Amt
Method Of Determining Revenues	FAIR MARKET VALUE	MethodOfDeterminingRevenuesTxt

Other Non Cash Contri Table OtherNonCashContriTableGrp (2 entries)

Non Cash CheckboxNonCashCheckboxInd	DescDesc	ContributionContributionCnt	Noncash Contributions Rpt F990NoncashContributionsRptF990Amt	Method Of Determining RevenuesMethodOfDeterminingRevenuesTxt
Yes (X)	PRINTED ITEMS	6	$37,254	FAIR MARKET VALUE
Yes (X)	VARIOUS OTHER	19	$68,237	FAIR MARKET VALUE

Field	Value	IRS element (for citing)
Any Property That Must Be Held	false	AnyPropertyThatMustBeHeldInd
Review Process Unusual NC Gifts	Yes (true)	ReviewProcessUnusualNCGiftsInd
Third Parties Used	false	ThirdPartiesUsedInd

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	SCHEDULE M, PAGE 2, PART II	FormAndLineReferenceDesc
Explanation	PART I, COLUMN (B) LLS IS REPORTING THE NUMBER OF CONTRIBUTIONS FOR EACH OF THE ITEMS IN PART I, NOT THE NUMBER OF INDIVIDUAL ITEMS.	ExplanationTxt

Schedule O IRS990ScheduleO

Supplemental Information Detail SupplementalInformationDetail (12 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
FORM 990, PAGE 2, PART III, LINE 4A	A) RESEARCH PROGRAMS: AT LLS, WE ARE PUSHING BOUNDARIES TOWARD POWERFUL NEW THERAPIES. WE PROPEL GROUNDBREAKING CANCER TREATMENTS THROUGH ALL PHASES OF THE DRUG APPROVAL PROCESS AND ARE PROUD THAT OUR SUPPORT HAS BEEN KEY TO ADVANCING 75% OF THE ALMOST 100 BLOOD CANCER TREATMENT APPROVALS OVER THE LAST FIVE YEARS. AS WE CONTINUED TO SUPPORT THE SEARCH FOR LIFESAVING AND LESS TOXIC TREATMENTS IN 2022, WE INVESTED IN EXCITING RESEARCH FRONTIERS, INCLUDING PRECISION MEDICINE, IMMUNOTHERAPY, AND LINKS BETWEEN MUTATIONS AND BLOOD CANCER-ADVANCEMENTS THAT ARE CHANGING THE PARADIGM OF CANCER TREATMENT. IN THE PROCESS, WE PROPELLED SEVERAL NOVEL SCIENCE INITIATIVES TO NEW HEIGHTS-MANY OF WHICH HARDLY SEEMED POSSIBLE JUST A SHORT TIME AGO. WITH ADVISORY INPUT FROM RECOGNIZED BIOMEDICAL RESEARCH EXPERTS, LLS FUNDS EXEMPLARY PROJECTS ACROSS THE ENTIRE RESEARCH CONTINUUM RELEVANT TO IMPROVE OUTCOMES FOR BLOOD CANCER PATIENTS, FROM BASIC LABORATORY SCIENCE THROUGH CLINICAL TRIALS, AND FROM INVESTIGATOR-INITIATED RESEARCH TO PRIVATE-SECTOR DRUG DEVELOPMENT ALLIANCES. LLS IS DELIBERATE AND PURPOSEFUL IN FINDING AND SUPPORTING RESEARCH THAT IS MOST LIKELY TO HELP PATIENTS AS SOON AS POSSIBLE. TO DATE, LLS HAS INVESTED OVER 1.6 BILLION IN RESEARCH AIMED AT HELPING ALL BLOOD CANCER PATIENTS LIVE BETTER, LONGER LIVES. OUR SUSTAINED RESEARCH INVESTMENT OVER MULTIPLE DECADES HAS PAID OFF HANDSOMELY. THIS IS BEST DEMONSTRATED BY OUR SEMINAL INVESTMENT IN CHIMERIC ANTIGEN RECEPTOR T CELL (CAR T) THERAPY STARTING IN 1990 THAT, SINCE 2017, HAS TRANSLATED INTO A 12 FDA-APPROVED CAR T THERAPIES FOR ACUTE B-CELL LEUKEMIA, NON-HODGKIN LYMPHOMA, AND MULTIPLE MYELOMA. CAR T THERAPY HAS IN SOME CASES PRODUCED CURES IN PATIENTS WHO HAVE FAILED ALL OTHER THERAPEUTIC OPTIONS. IN FISCAL YEAR 2022, LLS SUPPORTED RESEARCH IN THE U.S., CANADA AND 9 OTHER COUNTRIES WITH A TOTAL RESEARCH DISBURSEMENT OF APPROXIMATELY 54.6 MILLION. RESEARCH FUNDING WAS DISTRIBUTED ACROSS ALL BLOOD CANCERS. IMPACT RESEARCH GRANTS TO ADDRESS UNEQUAL REPRESENTATION OF UNDERSERVED POPULATIONS IN CLINICAL TRIALS, IN MAY WE INTRODUCED IMPACT (INFLUENTIAL MEDICINE PROVIDING ACCESS TO CLINICAL TRIALS) RESEARCH GRANTS. AN INITIAL FIVE-YEAR INVESTMENT OF 3.75 MILLION WAS ALLOCATED TO MAYO CLINIC, VANDERBILT UNIVERSITY MEDICAL CENTER, AND WEILL CORNELL MEDICINE IN NEW YORK CITY. WE NOW HAVE SIX IMPACT RESEARCH GRANTS IN PLACE SINCE OCTOBER 2022. THE IMPACT GRANTS WILL HELP THESE MAJOR CANCER CENTERS EXPAND CLINICAL TRIAL ACCESS TO LOCAL COMMUNITY-BASED HOSPITALS AND CLINICS WITH SUBSTANTIAL UNDERSERVED POPULATIONS. THE GOAL IS TO INCREASE TRIAL ENROLLMENT AMONG TRADITIONALLY UNDERSERVED POPULATIONS, INCLUDING RACIAL AND ETHNIC MINORITIES, RURAL RESIDENTS, AND INDIVIDUALS WITH LOW INCOME, TO AT LEAST 20%, THEREBY EXPANDING ACCESS TO STATE-OF-THE-ART THERAPIES TO A BROADER SWATH OF NEWLY DIAGNOSED BLOOD CANCER PATIENTS. THERAPY ACCELERATION PROGRAM (TAP) SINCE 2007, OUR INNOVATIVE VENTURE PHILANTHROPY INITIATIVE, THE LLS THERAPY ACCELERATION PROGRAM (TAP), HAS PARTNERED WITH OVER 70 BIOTECHNOLOGY COMPANIES AND ACADEMIC RESEARCHERS TO EXTEND THE THERAPEUTIC LANDSCAPE IN LEUKEMIA, LYMPHOMA, AND MULTIPLE MYELOMA BY INVESTING OVER 130 MILLION DOLLARS, AND SO FAR, LEADING TO 3 FDA APPROVALS. CURRENTLY, THERE ARE OVER 20 ACTIVE CLINICAL STUDIES WITH TAP-SUPPORTED THERAPIES, INCLUDING 4 LATE- STAGE CLINICAL STUDIES WITH CLINICAL DATA EXPECTED IN THE NEXT YEAR OR TWO THAT COULD LEAD TO NEW FDA APPROVALS FOR BLOOD CANCER PATIENTS. IN 2022, WE MADE FOUR INVESTMENTS IN COMPANIES DEVELOPING NEXT-GENERATION IMMUNOTHERAPIES INCLUDING TWO FROM EUROPE. THESE INVESTMENTS GO BEYOND THE TRADITIONAL T CELL THERAPY SUCH AS CAR-T OR BI-SPECIFICS AND INCLUDE TWO CHECKPOINT INHIBITORS USING MACROPHAGES OR MYELOID CELLS TO ELICIT THE ANTI-CANCER EFFECTS. WE ALSO INVESTED IN COMPANIES DEVELOPING NOVEL ANTIBODIES, ONE A GAMMA-DELTA T CELL ACTIVATING ANTIBODY FOR A VARIETY OF BLOOD CANCERS AND ANOTHER ANTIBODY FOR A NOVEL TARGET IN PATIENTS WITH RARE BLOOD CANCERS INCLUDING LARGE GRANULAR LYMPHOCYTIC LEUKEMIA AND CYTOTOXIC LYMPHOMAS WHERE THERE IS NO STANDARD OF CARE AND CURRENT THERAPIES ARE TOO TOXIC FOR PATIENTS. ALL FOUR COMPANIES ARE IN ACTIVE CLINICAL DEVELOPMENT IN BLOOD CANCERS. NATIONAL PATIENT REGISTRY COVID INFORMATION THE ONGOING COVID-19 PANDEMIC ENGENDERED A HOST OF FEARS AND QUESTIONS FOR THE BLOOD CANCER COMMUNITY. WHEN PATIENT CONCERNS AROSE ABOUT WHETHER THE NEW VACCINES WOULD PROTECT THEM, LLS STEPPED IN TO FIND ANSWERS. IN FEBRUARY 2021, LLS ACTIVATED THE LLS NATIONAL PATIENT REGISTRY, A PROJECT SUPPORTED BY ETHEL AND BERNARD GARIL IN MEMORY OF THEIR SON, MICHAEL, WHO SUCCUMBED TO ACUTE LYMPHOBLASTIC LEUKEMIA. MORE THAN 10,000 BLOOD CANCER PATIENTS ANSWERED THE CALL TO JOIN THE REGISTRY AS "CITIZEN SCIENTISTS." THIS ALLOWED US TO GENERATE THE LARGEST DATA SET REPORTED TO DATE ON VACCINE SAFETY AND EFFICACY(INCLUDING BOOSTERS) ACROSS ALL MAJOR BLOOD CANCER AND TREATMENT TYPES. THIS INFORMATION HAS HELPED PATIENTS, HEALTHCARE PROVIDERS, AND PUBLIC HEALTH OFFICIALS MAKE MORE INFORMED CHOICES ABOUT COVID-19 PREVENTION. CLINICAL TRIALS BEAT AML MASTER TRIAL BEGINNING NOVEMBER 2016, LLS LAUNCHED THE BEAT AML MASTER TRIAL, A COLLABORATIVE CLINICAL TRIAL TESTING SEVERAL NOVEL TARGETED THERAPIES FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) DESIGNED TO FACILITATE FDA APPROVAL OF NEW DRUGS AND CHANGE THE TREATMENT PARADIGM FOR PATIENTS DIAGNOSED WITH AML BY DEVELOPING MORE INDIVIDUALIZED, EFFECTIVE TREATMENT APPROACHES. THE MASTER TRIAL INVOLVES COLLABORATIONS WITH MULTIPLE MEDICAL INSTITUTIONS, DRUG COMPANIES, A GENOMIC PROVIDER, A CLINICAL RESEARCH ORGANIZATION, AND THE FDA, ALL OF WHOM HAVE COMMITTED TO WORKING COLLABORATIVELY. PEDAL MASTER TRIAL IN 2022, LLS LAUNCHED LLS' PEDIATRIC ACUTE LEUKEMIA (PEDAL) MASTER CLINICAL TRIAL. THIS UNPRECEDENTED INTERNATIONAL COLLOBORATION BETWEEN LLS, THE NATIONAL CANCER INSTITUTE (NCI), THE CHILDREN'S ONCOLOGY GROUP (OCG) AND OTHER PARTNERS BREAKS NEW GROUND, BRINGING PRECISION MEDICINE TO THE TREATMENT OF PEDIATRIC RELAPSED ACUTE LEUKEMIA. RATHER THAN A "ONE SIZE FITS ALL" APPROACH, PEDAL USES GENOMICS AND OTHER BIOMARKERS TO CUSTOMIZE TREATMENT, ALLOWING INNOVATIVE THERAPIES TO BE MATCHED TO PATIENTS BASED ON THEIR UNIQUE TUMOR BIOLOGY. A WIDE RANGE OF TRIAL SCREENIN LOCATIONS - SPANNING EUROPE, AUSTRALIA, NEW ZEALAND, CANADA, AND OVER 200 US SITES - ENSURES WIDESPREAD PARTICIPATION. ARKANSAS CHILDRESN'S HOSPITAL BECAME THE FIRST US THERAPEUTIC TRIAL SITE IN 2022, WITH MORE TO COME.
FORM 990, PAGE 2, PART III, LINE 4B	B) PATIENT & COMMUNITY SERVICES: AN ESTIMATED 1.5 MILLION PEOPLE ACROSS THE UNITED STATES (US) ARE CURRENTLY LIVING WITH OR ARE IN REMISSION FROM LEUKEMIA, LYMPHOMA AND MYELOMA. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) OFFERS AN ARRAY OF FREE, COMPREHENSIVE RESOURCES TO BLOOD CANCER PATIENTS, CAREGIVERS, FAMILIES AND FRIENDS OF PATIENTS, ADVOCATES, HEALTHCARE PROFESSIONALS AND THE PUBLIC. LLS IS COMMITTED TO PROVIDING THE MOST ACCURATE AND UP-TO-DATE BLOOD CANCER INFORMATION. PROFESSIONAL VOLUNTEER CLINICAL ADVISORS WORK WITH LLS STAFF TO REVIEW ALL OF THE INFORMATION LLS PROVIDES THROUGH HEALTHCARE PROFESSIONAL AND PATIENT EDUCATION PROGRAMS, PUBLICATIONS AND THE LLS WEBSITE. SUPPORT SERVICES ARE PROVIDED BY PROFESSIONALS OR RIGOROUSLY TRAINED PEER VOLUNTEERS. ALL RESOURCES ARE PROVIDED THROUGH A VARIETY OF MEDIA - PRINT, ONLINE, BY PHONE, AND FACE-TO-FACE IN COMMUNITIES. A NUMBER OF RESOURCES ARE AVAILABLE IN SPANISH FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. FINANCIAL ASSISTANCE OUR FINANCIAL ASSISTANCE PROGRAMS AIM TO LESSEN THE ECONOMIC TOLL ON PATIENTS AND FAMILIES TO HELP PATIENTS AFFORD LIFE-SAVING TREATMENTS. TO COUNTER CONTINUALLY RISING DRUG PRICES AND ALLEVIATE THE BURDENS FELT BY PATIENTS COPING WITH BLOOD CANCER, WE PROVIDED MORE THAN 75,400 PATIENTS WITH OVER 384M IN ASSISTANCE AWARDED, A 59% INCREASE OVER LAST YEAR. THE LION'S SHARE-OVER 371 MILLION- AWARDED TO SUPPORTED PATIENTS' INSURANCE PREMIUMS AND TREATMENT-RELATED CO-PAY AND CO-INSURANCE OUT OF POCKET COSTS THROUGH OUR CO-PAY ASSISTANCE PROGRAM. IN KEEPING WITH OUR COMMITMENT TO DIVERSITY, EQUITY, AND INCLUSION, LLS RECOGNIZES THAT NEED EXISTS THROUGHOUT ALL GEOGRAPHIC REGIONS AND WITHIN ALL PATIENT POPULATIONS, INCLUDING THOSE TRADITIONALLY UNDERREPRESENTED. IN FY22, FINANCIAL ASSISTANCE WAS PROVIDED TO PATIENTS WHO RESIDED IN 82% OF ALL U.S. COUNTIES AND 74% OF THE COUNTIES ACROSS THE U.S. WITH THE HIGHEST POVERTY RATES. CO-PAY ASSISTANCE PROGRAM THE CO-PAY ASSISTANCE PROGRAM SUPPORTS QUALIFYING BLOOD CANCER PATIENTS MEET THEIR HEALTH INSURANCE OR MEDICARE PLAN PART B OR D PREMIUMS OR CO- PAYMENT OBLIGATIONS RELATED TO TREATING THEIR BLOOD CANCER DIAGNOSIS. PATIENTS WITH PRESCRIPTION DRUG COVERAGE, MEDICARE BENEFICIARIES UNDER MEDICARE PART B AND/OR MEDICARE PART D, MEDICARE SUPPLEMENTARY HEALTH INSURANCE OR MEDICARE ADVANTAGE SHOULD CHECK WITH LLS TO SEE IF THEY MEET ELIGIBILITY REQUIREMENTS TO RECEIVE FINANCIAL SUPPORT. CO-PAY ASSISTANCE IS SUBJECT TO FUNDING AVAILABILITY BY SPECIFIC BLOOD CANCER DIAGNOSIS. IN 2022, CO-PAY ASSISTANCE WAS PROVIDED TO OVER 36,800 PATIENTS. SUSAN LANG PRE CAR T-CELL THERAPY TRAVEL ASSISTANCE PROGRAM LLS PROVIDED OVER 420 GRANTS, EACH 2,500, FOR TREATMENT-RELATED TRANSPORTATION AND LODGING COSTS FOR PATIENTS WHO ARE BEING EVALUATED TO RECEIVE CAR T-CELL THERAPY AS EITHER STANDARD TREATMENT OR A CLINICAL TRIAL. SUSAN LANG PAY-IT-FORWARD PATIENT TRAVEL ASSISTANCE PROGRAM LLS AWARDED A 500 GRANT TO OVER 11,050 PATIENTS FOR TREATMENT-RELATED TRANSPORTATION AND LODGING COSTS. URGENT NEED PROGRAM IN PARTNERSHIP WITH MOPPIE'S LOVE AND CHARLIE'S FUND, LLS PROVIDED A 500 GRANT TO NEARLY 11,750 PATIENTS AND FAMILIES IN ACUTE FINANCIAL NEED FOR NON-MEDICAL LIVING EXPENSES-INCLUDING RENT, UTILITIES, AND FOOD. PATIENT AID PROGRAM LLS AWARDED ONE-TIME STIPENDS OF 100 TO OVER 15,400 PATIENTS TO HELP OFFSET NON-MEDICAL EXPENSES. SCHOLARSHIP FOR BLOOD CANCER SURVIVORS IN 2022, THE LLS SCHOLARSHIP FOR BLOOD CANCER SURVIVORS PROVIDED UP TO 7,500 IN TUITION SUPPORT TO 100 PATIENTS, FOR VIRTUAL OR IN-PERSON VOCATIONAL, TWO-YEAR, OR FOUR-YEAR UNDERGRADUATE EDUCATION.
FORM 990, PAGE 2, PART III, LINE 4C	C) PUBLIC HEALTH EDUCATION: LLS BELIEVES KNOWLEDGE IS POWER. AS ALWAYS, LLS HAS OFFERED THEIR INFORMATIONAL PROGRAMS IN VIRTUAL FORMATS, CONTINUING TO PROVIDE VITALLY NEEDED EDUCATION AND EMOTIONAL SUPPORT FOR THOSE IMPACTED BY BLOOD CANCER. ONGOING PANDEMIC CONCERNS TRAINED ONCOLOGY INFORMATION SPECIALISTS IN OUR INFORMATION RESOURCE CENTER (IRC) WERE AVAILABLE TO ANSWER PANDEMIC-RELATED AND OTHER QUESTIONS. NEARLY 26,000 INTERACTIONS BETWEEN THE IRC AND PATIENTS AND CAREGIVERS TOOK PLACE, WITH AVERAGE CALL LENGTHS UP 14% OVER 2021. FACILITATING CLINICAL TRIAL ACCESS THE LLS CLINICAL TRIAL SUPPORT CENTER (CTSC) GREW THROUGHOUT THE YEAR AS WE INCREASED OUR BI-LINGUAL AND PEDIATRIC EXPERTISE AMONG THE CTSC NURSE NAVIGATORS, AND CONTINUED TO EXPAND THE POSSIBILITY OF POSITIVE OUTCOMES FOR PATIENTS BY MATCHING THEM TO SUITABLE CLINICAL TRIALS. OUR NURSE NAVIGATORS ASSISTED 1,005 PATIENTS (ABOUT THE SAME AS IN 2021). OF THE 751 NEW PATIENTS ASSISTED, 19% ENTERED A TRIAL. OUTREACH TO UNDERSERVED GROUPS WE AUGMENTED EFFORTS TO EXPAND ACCESS TO LLS SERVICES AND RESOURCES BY BOLSTERING RELATIONS WITH COMMUNITY GROUPS AND LEADERS, NOTABLY IN THE BLACK AND LATINO COMMUNITIES, AND INCREASED OUR NUMBER OF BILINGUAL VOLUNTEERS. WE ALSO INCREASED ACCESSIBILITY OF OUR EDUCATION PROGRAMS TO RURAL PATIENTS AND FAMILIES VIA OUR VIRTUAL OFFERINGS. MOREOVER, WE EXPANDED PARTNERSHIPS WITH AFFINITY GROUPS INCLUDING: THE NATIONAL COALITION OF 100 BLACK WOMEN, THE BLACK CAUCUS OF THE AMERICAN LIBRARY, VISIONS Y COMPROMISO AND THE MEXICAN CONSULATE'S VENTANILLA DE SALUD PROGRAM. THE LLS MYELOMA LINK PROGRAM, LAUNCHED IN 2017, CONTINUED TO GAIN TRACTION. WE IMPROVED UNDERSTANDING OF TREATMENT OPTIONS BY PROVIDING IMPORTANT INFORMATION TO AFRICAN AMERICANS, WHO ARE TWICE AS LIKELY TO BE DIAGNOSED WITH MULTIPLE MYELOMA AS CAUCASIAN AMERICANS. IN 2022, LLS REACHED NEARLY 22,000 PEOPLE THROUGH MORE THAN 60 MYELOMA LINK EDUCATION AND OUTREACH ACTIVITIES IN 13 CITIES. EDUCATION AND PATIENT CONNECTIONS OUR VIRTUAL EDUCATION PROGRAMS PROVIDED BOTH PATIENTS AND FAMILIES, AS WELL AS HEALTH CARE PROFESSIONALS, ACCESS TO CONTENT INCLUDING BLOOD CANCER CONFERENCES, LOCAL EDUCATION PROGRAMS, NATIONAL WEBINARS, VIDEOS, LECTURES, AND PODCASTS. LLS'S HIGHLY VIEWED WEBSITE CONTINUES TO PROVIDE THE MOST UP TO DATE BLOOD CANCER INFORMATION INCLUDING ACCESS TO BLOGS, BOOKLETS, WORKBOOKS, FACT SHEETS AND MORE. IN ADDITION, 1,060 CANCER PATIENTS WERE PROVIDED WITH PERSONALIZED NUTRITION CONSULTATIONS BY LLS'S REGISTERED DIETITIAN. OUR PATIENT & COMMUNITY OUTREACH TEAM CONTINUED TO BRING PATIENTS TOGETHER VIA ONLINE LOCAL SUPPORT GROUPS AND CHATS. THE PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM MATCHED NEARLY 2,100 PATIENTS (UP 17% FROM 2021) WITH TRAINED VOLUNTEERS FACING THE SAME DISEASE, HELPING TO AVERT PANDEMIC-RELATED ISOLATION. IN ADDITION, MEMBERSHIP IN LLS COMMUNITY-OUR ONLINE SOCIAL NETWORK- WAS 19,181, AN INCREASED 8% OVER 2021.
FORM 990, PAGE 2, PART III, LINE 4D	D) PROFESSIONAL EDUCATION: LLS SERVES THE EDUCATIONAL NEEDS OF THE MEDICAL AND RESEARCH COMMUNITY THROUGH A NUMBER OF PROFESSIONAL EDUCATION SYMPOSIA OFFERED THROUGHOUT THE YEAR. THE EDUCATIONAL PROGRAM OFFERS VARYING FORMATS TO FACILITATE THE EXCHANGE OF INFORMATION AND IDEAS ON THE NEWEST DEVELOPMENTS IN CANCER RESEARCH AND TREATMENT. UPCOMING AND ARCHIVED CE/CME PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/CE. IN FY 2022: -LLS PROVIDED 14 CME/CE-GRANTING VIRTUAL EDUCATIONAL PROGRAMS, WITH 873 HEALTHCARE PROFESSIONALS IN ATTENDANCE. - OVER 28,000 PATIENTS AND PROFESSIONALS PARTICIPATED IN LIVE EDUCATION PROGRAMS DELIVERED VIRTUALLY AS WELL AS DELIVERED IN PERSON, LOCALLY AND REGIONALLY. --THERE WERE 104,173 PAGE VIEWS FOR ARCHIVED WEB PROGRAMS, 35,663 VIRTUAL LECTURE VIEWS AND 97,685 PODCAST DOWNLOADS.
FORM 990, PART V, LINE 4B	CANADA
FORM 990, PAGE 6, PART VI, LINE 4	IN JULY 2022, THE LLS BOARD APPROVED TWO NEW COMMITTEES - THE TALENT & COMPENSATION COMMITTEE AND THE THERAPY ACCELERATION PROGRAM COMMITTEE.
FORM 990, PAGE 6, PART VI, LINE 11B	THE FORM 990 WAS PREPARED BY THE LLS FINANCE DEPARTMENT AND WAS REVIEWED BY THE CFO, SENIOR VICE PRESIDENT OF FINANCE, VICE PRESIDENT, CONTROLLER, AND KPMG FOR COMMENT AND SUGGESTED REVISIONS. THE FORM 990 WAS THEN PROVIDED TO THE AUDIT COMMITTEE, WHICH IS A COMMITTEE OF THE BOARD OF DIRECTORS. THE AUDIT COMMITTEE REVIEWED THE 990 AND PROVIDED INPUT PRIOR TO FILING. THE FINAL DRAFT FORM 990, AS WILL BE FILED WITH THE IRS, WAS PROVIDED TO THE ENTIRE BOARD OF DIRECTORS PRIOR TO FILING WITH THE IRS.
FORM 990, PAGE 6, PART VI, LINE 12C	ALL EMPLOYEES, VOLUNTEERS, CONSULTANTS, TEMPORARY EMPLOYEES, LOCAL BOARD MEMBERS, AND MEMBERS OF THE NATIONAL BOARD OF DIRECTORS ARE REQUIRED TO REVIEW THE CONFLICT OF INTEREST POLICY ON AN ANNUAL BASIS AND SUBMIT A SIGNED FORM ACKNOWLEDGING THAT THEY HAVE REVIEWED THE POLICY AND DISCLOSED ANY CONFLICTS OF INTEREST. ALL CONFLICT OF INTEREST DISCLOSURE FORMS ARE REVIEWED BY THE LEGAL DEPARTMENT AND, IF DEEMED NECESSARY, ESCALATED TO THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS FOR FURTHER REVIEW, EVALUATION, AND/OR MANAGEMENT OF ANY ACTUAL OR APPARENT CONFLICTS OF INTEREST.
FORM 990, PAGE 6, PART VI, LINE 15A	THE EXECUTIVE COMMITTEE COMPRISED OF INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS REVIEWS, MONITORS, AND APPROVES THE CHIEF EXECUTIVE OFFICER'S PERFORMANCE AND COMPENSATION. THEIR DECISION IS INCLUDED IN THE APPROPRIATE MINUTES OF THE MEETING IN WHICH APPROVAL WAS GIVEN. IN JUNE 2022, THE EXECUTIVE COMMITTEE, THROUGH AN INDEPENDENT THIRD PARTY, OBTAINED A MARKET STUDY COMPRISED OF SIMILAR NOT-FOR-PROFIT ORGANIZATIONS TO REVIEW THE COMPENSATION MARKET LEVELS AND SET THE CHIEF EXECUTIVE'S SALARY COMMENSURATELY. THE COMMITTEE MET, APPROVED AND DOCUMENTED THE PROCESS IN THE COMMITTEE MINUTES.
FORM 990, PAGE 6, PART VI, LINE 15B	IN 2020, THE EXECUTIVE COMMITTEE, THROUGH AN INDEPENDENT THIRD PARTY, OBTAINED A MARKET STUDY COMPRISED OF SIMILAR NOT-FOR-PROFIT ORGANIZATIONS TO REVIEW THE COMPENSATION MARKET LEVELS OF OTHER OFFICERS AND KEY EMPLOYEES AND TO APPROVE THE PRESIDENT AND CEO'S RECOMMENDATIONS ON THEIR COMPENSATION LEVELS.
FORM 990, PAGE 6, PART VI, LINE 17	ILLINOIS, INDIANA, KANSAS, KENTUCKY, LOUISIANA, MASSACHUSETTS, MARYLAND, MAINE, MICHIGAN, MINNESOTA, MISSOURI, MISSISSIPPI, NEW HAMPSHIRE, NEW JERSEY, NEW MEXICO, NEBRASKA, NEW YORK, OHIO, OKLAHOMA, OREGON, PENNSYLVANIA, PUERTO RICO, RHODE ISLAND, SOUTH CAROLINA, TENNESSEE, UTAH, VIRGINIA, WASHINGTON, WISCONSIN, WEST VIRGINIA
FORM 990, PAGE 6, PART VI, LINE 19	THE LEUKEMIA & LYMPHOMA SOCIETY, INC. MAKES ITS ANNUAL FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC ON ITS WEBSITE AT WWW.LLS.ORG. ITS GOVERNING DOCUMENTS ARE MADE AVAILABLE UPON REQUEST FOR PUBLIC INSPECTION. ANY IDENTIFIED CONFLICTS OF INTEREST ARE DISCLOSED IN THE 990.

Schedule R IRS990ScheduleR

Id Disregarded Entities IdDisregardedEntitiesGrp (8 entries)

Address Line1USAddress/AddressLine1Txt	CityUSAddress/CityNm	State AbbreviationUSAddress/StateAbbreviationCd	ZIPUSAddress/ZIPCd	Primary ActivitiesPrimaryActivitiesTxt	Legal Domicile StateLegalDomicileStateCd	Total IncomeTotalIncomeAmt	End Of Year AssetsEndOfYearAssetsAmt	Business Name Line1DirectControllingEntityName/BusinessNameLine1Txt
BEAT AML LLC
3 INTERNATIONAL DRIVE	RYE BROOK	NY	10573	RESEARCH	NY	$8,348,268	-$439,113	LLS
LLS PEDAL INITIATIVE LLC
3 INTERNATIONAL DRIVE	RYE BROOK	NY	10573	RESEARCH	NY	$3,249,974	-$5,676,466	LLS
LLS TAP MIRAGEN LLC
3 INTERNATIONAL DRIVE	RYE BROOK	NY	10573	RESEARCH	NY			LLS
LLS TAP X4 LLC
3 INTERNATIONAL DRIVE	RYE BROOK	NY	10573	RESEARCH	NY		$289,500	LLS
LLS TAP LLC
3 INTERNATIONAL DRIVE	RYE BROOK	NY	10573	RESEARCH	NY	-$31,819,717	$266,676	LLS
LLS TAP CONSTELLATION LLC
3 INTERNATIONAL DRIVE	RYE BROOK	NY	10573	RESEARCH	NY			LLS
LLS TAP KDAC LLC
3 INTERNATIONAL DRIVE	RYE BROOK	NY	10573	RESEARCH	NY			LLS
STOP MDS LLC
3 INTERNATIONAL DRIVE	RYE BROOK	NY	10573	RESEARCH	NY			LLS

Id Related Tax Exempt Org IdRelatedTaxExemptOrgGrp (3 entries)

Address Line1USAddress/AddressLine1Txt	CityUSAddress/CityNm	State AbbreviationUSAddress/StateAbbreviationCd	ZIPUSAddress/ZIPCd	EINEIN	Primary ActivitiesPrimaryActivitiesTxt	Legal Domicile StateLegalDomicileStateCd	Exempt Code SectionExemptCodeSectionTxt	Public Charity StatusPublicCharityStatusTxt	Business Name Line1DirectControllingEntityName/BusinessNameLine1Txt	Controlled OrganizationControlledOrganizationInd	Address Line1ForeignAddress/AddressLine1Txt	CityForeignAddress/CityNm	CountryForeignAddress/CountryCd	Foreign PostalForeignAddress/ForeignPostalCd	Legal Domicile Foreign CountryLegalDomicileForeignCountryCd
THE LLS RESEARCH PROGRAMS INC
3 INTERNATIONAL DRIVE	RYE BROOK	NY	10573	133470494	PART VII	DE	501C3	12A	LLS INC	Yes (true)
THE LLS RESEARCH FOUNDATION
3 INTERNATIONAL DRIVE	RYE BROOK	NY	10573	133709252	PART VII	DE	501C3	12A	LLS INC	Yes (true)
THE LLS OF CANADA
					PART VII				NA	false	804 2 LANSING SQUARE	TORONTO	CA	M2J4P8	CA

Field	Value	IRS element (for citing)
Receipt Of Int Annts Rnts Rylts	false	ReceiptOfIntAnntsRntsRyltsInd
Gift Grnt Or Cap Contri To Oth Org	false	GiftGrntOrCapContriToOthOrgInd
Gift Grnt Cap Contri From Oth Org	false	GiftGrntCapContriFromOthOrgInd
Loans Or Guarantees To Other Org	false	LoansOrGuaranteesToOtherOrgInd
Loans Or Guarantees From Oth Org	false	LoansOrGuaranteesFromOthOrgInd
Div Related Organization	false	DivRelatedOrganizationInd
Asset Sale To Other Org	false	AssetSaleToOtherOrgInd
Asset Purchase From Other Org	false	AssetPurchaseFromOtherOrgInd
Asset Exchange	false	AssetExchangeInd
Rental Of Facilities To Oth Org	false	RentalOfFacilitiesToOthOrgInd
Rental Of Fclts From Oth Org	false	RentalOfFcltsFromOthOrgInd
Perform Of Services For Oth Org	false	PerformOfServicesForOthOrgInd
Perform Of Services By Other Org	false	PerformOfServicesByOtherOrgInd
Sharing Of Facilities	false	SharingOfFacilitiesInd
Paid Employees Sharing	false	PaidEmployeesSharingInd
Reimbursement Paid To Other Org	false	ReimbursementPaidToOtherOrgInd
Reimbursement Paid By Other Org	Yes (true)	ReimbursementPaidByOtherOrgInd
Transfer To Other Org	false	TransferToOtherOrgInd
Transfer From Other Org	false	TransferFromOtherOrgInd

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	SCHEDULE R	FormAndLineReferenceDesc
Explanation	THE LEUKEMIA & LYMPHOMA SOCIETY OF CANADA CARRIES OUT THE SAME PRIMARY ACTIVITIES AS THE LEUKEMIA & LYMPHOMA SOCIETY, INC. IN CANADA. THE LEUKEMIA SOCIETY RESEARCH PROGRAMS, INC. AND THE LEUKEMIA RESEARCH FOUNDATION, INC. SUPPORT THE ACTIVITIES OF THE LEUKEMIA & LYMPHOMA SOCIETY, INC.	ExplanationTxt